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Chapter 1
General Introduction & Objectives
1.1 Single-Use-Technologies in Biopharmaceutical
Manufacturing
Single-Use System (SUS) technology has increasingly emerged as the processing equipment
of choice for modern biopharmaceutical lines [1, 2], as depicted in Figure 1.1. These
polymer-based, ready-to-use systems were initially designed as lab-scale equipment for pilot
projects. Recently SUSs including large-scale disposable bioreactors, storage bags, mixing
systems, tubing, sensors, connectors, filter cartridges and chromatography systems, have
become widely deployed throughout up- and downstream processing [3, 4]. The disposable
concept is an innovative alternative to fixed stainless steel equipment, as it can outperform
the latter in terms of flexibility, productivity and handling. Recently, the technology has
become even more attractive being applicable to a more comprehensive product range
and size scale [5]. The variety of available SUS components facilitates end-to-end single-
use manufacturing facilities [6]. This modular approach of SUSs makes a customized
configuration of unit operations possible and can be adapted in a product-specific way to
save space and to provide the ease of maneuverability around the facility [7]. In addition to
the saving of work space, the application of SUSs can reduce costs by up to 50%. Among
other factors this is due to the elimination of cleaning validations especially in the case
of multi-product lines. By implementing a single-use 3D bag for buffer preparation and,
hence, avoiding the need of cleaning intervals, Weitbrecht et al. [8] were able to significantly
increase the productivity from 2.5 to 4 batches per week. However, despite many distinct
advantages of SUSs, the industry-wide application remains low (10%) with a market growth
reported to be around 20% in the past three years [9]. This rather low number is mainly
based on the concern of pharmaceutical-manufacturers that polymer-related impurities,
so called “leachables”, might migrate into the production stream and persist throughout
the manufacturing process (Fig. 1.1) [1]. As the main advantage of disposable systems
stem from the lower risk of cross-contamination and thus increased patient safety [10], a
contamination by leachables that can be of toxicological concern would be contrary and
has to be monitored.
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Figure 1.1: Comparison of assets and drawbacks of single-use system applications. Left:
Biopharmaceutical manufacturing site fully equipped with disposables, enabling a config-
urable solution for the final formulation step (Production line, Roche Diagnostics GmbH,
Mannheim Germany. Rights reserved). Right: Main factors restricting the use of dispos-
able systems by biomanufacturers. The primary concern is the presence of leachables and
extractables[1].
1.2 Polymer Additives and Possible Impurities
A number of additives are used in the processing of SUSs and pose risk as potential impu-
rities. While these additives tend to be soluble in solvents, are volatile or interact with the
product, they can potentially leach out of the polymer matrix. Due to direct contact of
the SUSs to the reagents, reaction solutions, intermediates and drug products during the
production process, these substances can potentially end up as leachables in the final drug
product formulation, hence eventually contaminating the pharmaceutical product [11, 12].
Among these impurities are low molecular weight substances that originated from the
polymer production process and remained in the polymer matrix, including initiators, sol-
vents, crosslinking substances, block builders and unpolymerized monomers [13, 14, 15, 16].
These substances do not have covalent bonds to the matrix and can easily migrate through
the polymer matrix. Further additive compounds are required to enable extrusion process-
ing. These additives can include lubricants, flame-retardants, adhesion promoters and slip
agents [17]. While necessary for the polymer processing, these additives can potentially
impair the drug product.
Further compounding is done to achieve desired material properties by adapting the
material to specific applications. These carefully selected additives are used to enhance
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performance, but can potentially migrate out of the polymer matrix into the drug product
under specific process conditions. The most commonly applied additives are plasticizers,
antioxidants and UV stabilizers [18]. Different polymers require different additives depend-
ing on the application. Hence, certain additives can be expected for some polymers but
not for others. The polymer polyvinyl chloride (PVC) for example, is in its pure form
comparatively rigid and requires plasticizers to provide a desired increase in flexibility and
formability [19, 20]. When a plasticizer is introduced to PVC, it affects the stress-strain
relationship of the constrained polymer chain, resulting in a reduction in stiffness [21].
Plasticizers, such as phthalates, enable a degradation in melt viscosity of the material as
well as an increase in its light stability and durability. They provide resistance to oxidizing
acids, but at the same time lower the polymer resistance to fungal contaminants. In order
to counteract, an approach of co-compounding of multiple additives in a single mixture is
adopted, where different preservatives and additional anti-infective agents are introduced
to the material. In the case, that certain properties cannot be achieved with one particular
polymer, multi-layer structures, in which layers of different polymers are combined, enable
an even wider range of properties [22]. However, each layer may feature different additives
with typically low molecular weight and impair the product. Hence, the potential a wider
spectrum of substances can pose risk as potential leachables.
In order to meet pharmaceutical needs single-use components have to be gamma-
sterilized prior to use. Resistance against oxidation during the sterilization procedure
and desirable durability are accomplished by antioxidant compounding [23]. This group
of additives can stabilize the polymer against high temperature and prevents degradation
over the operating lifetime induced by oxygen absorption [24]. There are two classes of an-
tioxidants: Primary antioxidants are free-radical scavengers, while secondary antioxidants
are classified as peroxide scavenger. These antioxidants, along with oxidized break-down
fragments, are commonly found as impurities [25]. Typically stabilizers are compounded
using UV-light in order to withstand oxidative deterioration. Besides organic stabilizers,
inorganic elements, such as barium, cadmium, cobalt, tin and lead can be used. Inorganic
reinforcement can be applied in form of fillers to reduce density and to improve stability,
like glass or mineral fibers in silicone tubing. Furthermore, non-soluble complexes of met-
als are classically applied as active catalyst and initiators for the polymerization process
[26, 27].
Development of novel and improved additives is an active area of research and new
substances are quickly adopted in polymer processing [11]. This further complicates the
determination of this broad set of diverse additives. To detect and quantify organic as well
as inorganic non-target substances, analytical techniques with appropriate sensitivity are
required. Depending on the organic substance’s volatility and polarity, gas chromatography
(GC) and complementary liquid chromatography (LC) in combination with mass spectrom-
etry (MS) are commonly applied [28, 29]. Consequently, only one example, long-chained
fatty acids used as lubricants are detected with LC analytic, compared to volatile sol-
vents, which are verified by GC-MS. For inorganic substances, inductively coupled plasma
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(ICP)-MS is applied.
1.3 Impact of Leachables and Extractables
The aim of this thesis is to monitor accumulation of leachables in drug products. This
investigation is warranted, as low binding substances in polymers are unavoidable and
can be harmful or potentially carcinogenic or genotoxic, posing a threat to the patient’s
health. In particular, as treatment duration can span several years up to a lifetime, even
trace concentrations down to ppb (µg/kg) or ppt (ng/kg) are to be considered as critical
thresholds to avoid any potential health hazards [30]. Parenteral pharmaceuticals are of
special concern, as leachables can get directly transferred into the bloodstream of a patient
and, thus, pose an increased safety risk [31].
Besides the immediate health risk due intake of leachables by the patient, another con-
cern is potential alteration of the product’s active ingredients leading to reduced efficacy
or other undesired side-effects [32]. In 1998 a first case of leachables causing an unan-
ticipated and adverse cross-reaction of pure red-cell aplasia (PRCA) was reported [33].
However, the leachables originated primarily in the packaging and not in SUSs. According
to the US Food and Drug Administration (FDA) in this instance chemical components
of the alkylphenol disulfide vulcanization agent within the rubber stopper of the Johnson
& Johnson’s Eprex pre-filled syringes were extracted by the drug component polysorbate
80 [34]. This reactive compound bound to the active protein, leading to a modification,
which in turn induced an immunomodulatory effect in patients. Affected patients even-
tually started producing antibodies against the very protein that was supposed to replace
their intrinsic EPO.
Other secondary effects can impact the appearance and other physical properties of the
product. For example acidic or basic leachables can shift the product’s pH-value. Leach-
ables with spectral property can influence discoloration, turbidity and high UV absorbance
in the product. Finally, leachables are also able to form particulate matters. In general
these secondary effects can again influence the efficacy of the drug product. A consumer
recall relating to an unusual moldy odor of the drug product Tylenol Arthritis Pain Caplet
100 was reported in 2010 [35], which was caused by the chemical 2,4,6-tribromoanisole
(TBA), a breakdown-product of the leachable tribromophenol (TBP). This substance is
used by wooden pallet manufacturers as a wood preservative and flame retardant. It mi-
grated through the drug packaging from the wooden transport pallets, entered the drug
product and caused gastrointestinal illness including nausea, vomiting and diarrhea.
To estimate the patient exposure and to ensure the integrity of the drug product it
is imperative to identify and quantify accumulation of leachables in the final product.
This includes testing for potential leachables in advance, before the actual SUS appli-
cation [36, 37, 38]. However, formulation information provided through Material Safety
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Data Sheet disclosures is typically incomplete or non-specific, as compounding is typically
carefully protected as intellectual property. Therefore, so called extractable-studies are
conducted [39, 40, 41]. These tests are performed to simulate worst case scenarios, in
order to identify substances that can be extracted by exposing the SUS to appropriate
solvents under exaggerated material stress including temperature and exposure time. This
approach induces increased leaching and is regulated through government agencies such
as the European Medical Affairs (EMA) [42] and the FDA [43]. Additionally, guidelines
are available through the USP (<665> review stage, <1665> [44, 45]) and FDA (US 21
CFR 211.65 [46]) specifying the evaluation of SUS compatibility with the drug formula-
tion. Beside authorities, industry collaboration groups such as the Bio-Process Systems
Alliance (BPSA), BioPhorum Operations Group (BPOG), American Society for Testing
and Materials (ASTM) International, International Society of Pharmaceutical Engineer-
ing (ISPE) and the American Society of Mechanical Engineers-Bioprocessing Equipment
(ASME-BPE) provide strategies on determining whether a single-use component has been
sufficiently and appropriately qualified. Although extractables can be considered a heuris-
tic approximation of potential leachables, not all extractables leach into drug products.
Furthermore, drug formulation components or buffers may interact with SUSs in various
ways and form leachables that were not previously identified during extractables analy-
sis with solvents [47]. Therefore, leachable studies of the whole manufacturing process are
highly warranted in addition to the extractable-footprints of each SUS, in order to elucidate
the actual leachable exposure and ensure the patient’s safety and the product’s integrity.
1.4 Objectives of this Thesis
The aim of this thesis was to obtain detailed information about the identities, the amount
and the toxicological properties of leachables detected in real-world industrial drug-filling
lines. This data can shed light on the potential actual patient exposure and can be used
to verify the concern of pharmaceutical manufacturers regarding SUS applications [1]. For
this purpose, samples of several intravenously administered protein drug formulations with
long treatment duration, representative of a pharmaceutical production portfolio, were ob-
served. Samples were drawn during the actual filling process after contact with various
SUSs with different polymer parts under production conditions. The general outline of
this thesis is depicted in Figure 1.2.
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SUS - Polymer-based Impurities
Leachable-study
Extractable-study
Analytical Evaluation SBSE:
- In combination with TD-GC-MS 
 Chapter II
- In combination with UPLC\QTOF-MS\MS
 Chapter IV
Leachable concentration over the filling process 
- ICH threshold
 Chapter IV
Study Design Evaluation:
- Thermal Extraction TD-GC-MS 
- Static Extraction GC-MS and ICP-MS
 Chapter III
Footprint of each SUS - Toxicological Classification
 Chapter IV
Simulation-study
Leachable concentration in mock setup
 Chapter V
Figure 1.2: Thesis outline in four chapters, describing three different study-designs for the
verification of polymer-based impurities, stem from SUSs in pharmaceutical processing. By
extractable footprints of each SUS, leachable testing of the whole pharmaceutical filling-
process was conducted as a classical approach. A potential risk-based approach was tested
in form of a simulation-study, combining the other two studies in one test.
Gaschromatography-mass spectroscopy (GC-MS) served as the primary analytic for
the experiments conducted in this thesis. An important aspect for the identification and
quantification of leachables in the drug products with interfering protein and surfactants
was the implementation of a pre-conditioning step. chapter 2 evaluates the applicability of
the stir-bar sorptive extraction (SBSE) as sample preparation prior to thermal desorption
(TD)-GC-MS for the detection of trace amounts of impurities in pharmaceutics. Tests
were performed to verify sufficient sensitivity, reproducibility and linearity over a broad
1.4 Objectives of this Thesis 7
spectrum of possible leachables with concentrations in the part per billion range and in
presence of different drug product matrices. Further, the effect of the stir-bar coating
material was examined and different optimization procedures were evaluated. Moreover,
we investigated the conditioning of the stir-bar to mitigate the inhibitory effects of the
drug matrix.
In chapter 3, the design of extractable-studies was adapted to identify impurities that
may leach from process equipment into the contacting solution during production, to pro-
vide qualitative data for the selection of target leachable-analysis. Therefore, different
harsh extraction methods were employed on the SUSs and assessed by their achieved
extraction-profiles. In addition static and thermal extraction of different single-use fil-
ters were conducted. For the static procedure WfI was used as extraction solution with
different pH-values and further an isopropanol/WfI mixture. Those extraction-procedures
were compared to the direct material thermal extraction at 150◦C. To ensure complete
analysis the diverse extractions were studied in combination with GC-MS analytic and
elemental impurity characterization with ICP-MS analytic.
In chapter 4 samples from real world filling lines were processed in order to detect leach-
able contamination. A differently coated stir-bar in combination with a solvent back ex-
traction (SBE) step with subsequent Ultra Performance Liquid Chromatography equipped
with a Quadrupole Time-of-Flight UPLC/QTOF-MS/MS analytic was used beside the
GC-MS application. The development and adoption of extractable-studies greatly facili-
tated the ability to address the trace amounts of complex leachables to their origin SUSs
in the process. These leachable-studies enabled to investigate if there was a link between
the amount of leachables and the filled protein based drug products with their different
formulations. Furthermore, SUSs with the highest leachable potential were identified for
each drug product. Finally, the amount of leachables and their toxicity and/or carcino-
genicity were evaluated by comparing to thresholds given by the ICH guideline M7, to
expose potential health hazards [30].
In chapter 5, simulation-studies were assessed as an alternative to the extractable/
leachable concept to evaluate the patients exposure to polymer-based impurities. The
new study-design was tested with the filling tube, which was reused up to six times in
consecutive filling batches. After each application, the remaining additives in the polymer
matrix of the tube were determined and compared to the extractable-footprint of an unused
tube. The comparison allowed a determination of the leached substances during the batch-
applications and even of substances, that were absorbed by the silicone. The new approach
was tested in regards to its applicability and sensitivity.
In the last chapter 6 a summary and outlook on new approaches for the detection of
polymer-based impurities in drug products is given.
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Chapter 2
Evaluation of Stir-Bar Sorptive
Extraction coupled with TD-GC-MS
Parts of the following chapter are published in the Journal of Pharmaceutical and
Biomedical Analysis, titled “Evaluation of stir-bar sorptive extraction coupled with
thermal desorption GC-MS for the detection of leachables from polymer single use
systems to drugs” [1]
Stir-bar sorptive extraction (SBSE) in combination with thermal desorption and gas chro-
matography-mass spectrometry (TD-GC-MS) is widely accepted as the gold–standard anal-
ysis method for trace amounts of organic substances, including leachables in aqueous matri-
ces. Meanwhile, as far as pharmaceutical quality control in protein-based parenteral drugs
is concerned, the use of SBSE analysis remains unexplored. Previous studies reported a
strong influence of the matrix on the method’s recovery. The scope of the present work
was to fill in the unexplored territory in a fourfold manner 1) by quantifying the effects
that various matrices commonly found in pharmaceutical processing have on the recovery,
2) by comparing between different coating materials for stir bar (namely between poly-
dimethylsiloxane (PDMS) material and ethylene-glycol (EG)-PDMS), 3) by determining
the concentration behavior of SBSE in alcoholic solutions compared to the direct injec-
tion and 4) by proposing among possible optimizations a preparation step for stir-bar to
mitigate inhibitory effects. The current study shows no inhibition of SBSE by protein
matrices (p > 0.15). Further the influence of various drug matrices on the recovery of
leachables with a log KO/W ≥ 3.6 is negligible (-3.9 to 3.8%). In contrast, the inhibition
effect caused by an alkaline media led to a recovery decrease of -42.9%. For leachables with
a log KO/W < 3.6, the relative recovery in the presence of various proteins ranged from
-72.8% to 15.6%, depending on the excipients of the drug product and not on the protein
itself. The highest loss in sensitivity was observed when the excipient benzyl alcohol was
present in the drug. Nonetheless, the limit of detection for the tested leachables in the in-
hibitory matrices was still below 3 µg/L (ppb), due to the concentration behavior of SBSE.
Additionally, SBSE was observed to be quantitatively reliable in all tested drug matrices
for concentrations from 0.005 to 0.1 mg/mL (r2 > 0.992). On average, the conventional
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PDMS coating resulted in a 28-fold higher signal-to-noise ratio compared to EG-PDMS.
Moreover, the PDMS coated stir-bar reached better reconcentrate in inhibitory alcoholic
solutions. Furthermore, a broader range of leachables was detectable with the PDSM
coating. Preceding stir-bar preparation consisting of a simple soaking step improved the
enrichment by 14%, effectively lowering the limit of detection.
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Figure 2.1: Graphical abstract - Evaluation of the performance of the stir-bar sorptive
extraction (SBSE) technique in combination with TD-GC-MS analytic for the detection of
leachables in drug products. Determination of the influence by the drug matrix, stir-bar
coating and extraction procedure parameters on the SBSE recovery.
2.1 Introduction
Single-use systems (SUSs) are increasingly preferred in pharmaceutical production lines [2].
SUSs are polymers that contain certain low binding chemical substances that purposively
have been added (e.g. antioxidants and plasticizers) in order to achieve desired material
properties (preservation and flexibility), or unwontedly present such as production impu-
rities. These substances are not incorporated in the polymer structure, are usually of low
or medium molecular weight, and bear high potential to migrate into the drug product
as leachables [3, 4]. Since there exist leachables, that have been classified as genotoxic
and carcinogenic, and since international safety regulations have set an acceptable life-
time intake for such compounds in a daily dose as 1.5 µg [5], detection and monitoring
is paramount for safe and responsible manufacturing of pharmaceuticals. Contamination
monitoring requires measurement techniques that provide sufficient sensitivity for detec-
tion of trace amounts on the order of parts per billion (ppb).
Dispersive liquid-liquid extraction was routinely used for monitoring organic substances
in aqueous samples [6, 7, 8, 9]. Among others, the main drawback of this technique is the
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low substance recovery leading to poor sensitivity. Alternative extraction techniques are
the solvent free variants, the well-established stir-bar sorptive extraction (SBSE). SBSE
was introduced as sample enrichment technique for leachables in aqueous matrices [10],
allowing direct extraction of solutes from polar aqueous matrices [8, 9, 11]. The targeted
analyte is absorbed on the coating material, while the phenomenon is governed by the par-
tition coefficient of the substance between the coating and the matrix. After the thermal
desorption step, desorbed analytes are detected using gas chromatography mass spectrom-
etry (GC-MS).
Due to its excellent sensitivity, efficiency and availability, SBSE has a wide range of
applications. Previous studies have demonstrated the use of PDMS-coated devices for the
extraction of organic contaminants from various complex matrices such as beverages [12],
oily food components [13, 14], fatty animal tissue [15, 16], digestive fluids and plasma
[17, 18]. The sensitivity of SBSE depends on the partition coefficient, i.e., the relation
between the hydrophobicity of the PDMS coating and the hydrophilicity of the aqueous
matrix, and it might therefore be dependent on the composition of the matrix. Nonethe-
less, previous literature has reported excellent recovery for a wide range of complex and
challenging matrices [13]. Large proteins in biofluids have formerly been reported to inhibit
substance enrichment by fouling the absorption phase during extraction [19]. However, it
remains unclear if recovery by SBSE is impaired by proteins in parenteral drug products.
In this study, we evaluate the applicability of SBSE for the detection of trace amounts of
leachables in pharmaceutical manufacturing. We examine the optimal use of this technique
for protein-based drug matrices, including diverse excipients and pH-values, the effect of
the stir-bar coating material and evaluated the extraction and concentration behavior.
Moreover, we investigate the conditioning of the stir-bar to mitigate the inhibitory effects
of the drug matrix.
2.2 Materials and Methods
2.2.1 Experimental Set-up
SBSE analysis was performed using a 10 mm long glass-encapsulated magnetic stir-bar
coated with 22 µg of PDMS (TwisterTM, Gerstel GmbH, Mu¨lheim an der Ruhr, Germany).
The PDMS-layer is 0.5 mm thick, which corresponds to a volume of 24 µL. The analytes
absorbed on stir bar coating material were released to the system by using a thermal
desorption system (TDS 3, Gerstel GmbH) equipped with a multi-purpose autosampler
(TDS A2, Gerstel GmbH). In accordance with the relevant manufacturer guideline, the
stir-bars were used for a maximum of 50 applications. Furthermore, it was ensured that
the number of times the stir-bar has been used before is comparable for each stir-bar in a
set of experiments. The system was coupled with a gas chromatography mass spectrometer
(7890B GC-System, 5977A MSD, Agilent Technologies, Santa Clara, US) equipped with
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a 30 m column (DB-1 MS, Agilent Technologies) packed with 0.25 µm of PDMS coating.
The absorption of analytes by the PDMS is a thermodynamically driven process to reach
an equilibrium state of the analyte concentrations in water (cW ) and in the PDMS-phase
(cPDMS), corresponding to the analyte’s polarity [20]:
cPDMS = KPDMS/W ∗ cW (2.1)
The absorption is driven by the analyte’s partition coefficient KPDMS/W . The mass balance
for the initial analyte mass in the sample (msample) comprises the mass in the PDMS
(mPDMS) and in water (mW ):
msample = mPDMS +mW . (2.2)
Combining (2.1) and (2.1) yields
KPDMS/W =
cPDMS
cW
= mPDMS
mW
∗ VW
VPDMS
. (2.3)
Thus, the recovery of a substance by SBSE, defined as the extraction efficiency of the stir-
bar’s coating, depends on the analyte’s partition coefficient KPDMS/W and the phase ratio
between the aqueous sample and the PDMS coating (24 µL). Since the process of analyte
partitioning from water into the PDMS coating is comparable to the partitioning from
water into octanol the partition coefficient KPDMS/W is proportional to the octanol/water
distribution coefficient KO/W . Hence, the theoretical recovery can be described as
R[%] = mPDMS
msample
= 100/( Vsample
VPDMS ∗KO/W + 1) (2.4)
Therefore, the extraction of substances by the PDMS coating layer from aqueous sam-
ples of a volume of 5 mL is most effective (theoretical of recovery 95%) for substances
with partitioning coefficients of logKO/W greater than 3.6 [10]. In order to cover a broad
range of theoretical recoveries (high and low), two analytes as spiking standards were cho-
sen, namely: 3,5-di-tert-butyl-4-hydroxybenzaldehyde (BHT-aldehyde) with a log KO/W -
value of 4.2 (theoretical recovery of 98.7%) and tetrahydrofurfuryl-methacrylate (THF-
methacrylate) with a log KO/W -value of 1.8 (theoretical recovery of 23.24%). Both sub-
stances can be found in common drug manufacturing processes as leachables, which are a
plastic adhesive and an antioxidant, respectively (Table 2.1) [21, 22].
2.2.2 Chemicals and Materials
All spiking standards (see Tab. 2.1) (> 97%) were purchased from Sigma Aldrich (Stein-
heim am Albuch, Germany) and prepared in absolute ethanol (99.5%, Merck, Darmstadt,
Germany). For dilution purposes Water for Injection (WfI) was prepared on a Milli-Q
Advantage A10 system (Merck, Darmstadt, Germany). All tested drug products were ob-
tained from Roche Diagnostic GmBH (Mannheim, Germany). The tested excipient benzyl
alcohol (99%) and tritrisol buffer were purchased from Merck (Darmstadt, Germany). Fur-
ther, the three different surfactants were obtained from BASF (Ludwigshafen, Germany)
and isopropyl alcohol from VWR (Darmstadt, Germany) with a GC purity of 99.5%.
2.2 Materials and Methods 17
Table 2.1: Spiking standards used in the different experiments, along with the theoretical
recovery based on the log KO/W and the phase ratio (see equation (2.4)). These substances
can be found as potential leachables.
Experiment Spiking
Standard
[CAS No.]
log
KO/W
Theoretical
recovery
[%]
Average
mass
[Da]
Leachable
characteriza-
tion
Applied in all
experiments
Tetrahydro-
furfuryl
methacrylate
[2455-24-5]
1.80 23.2 170.2 Adhesive
Applied in all
experiments
3,5-Di-tert-
butyl-4-
hydroxy-
benzaldehyde
[1620-98-0]
4.20 98.7 234.3 Antioxidant;
BHT breakdown
product
Effects of drug
matrices; Stir-
bar coating
comparison
4-ethylphenol
[123-07-9]
2.55 63.0 122.1 Antioxidant 2,6-
di-tert-butyl-
4-ethylphenol
breakdown
product
Stir-bar coat-
ing comparison
Tris(2-
butoxyethyl)
phosphate
[78-51-3]
3.0 82.8 398.5 Flame retardant
Stir-bar coat-
ing comparison
Tetracosane
[646-31-1]
13.12 100 338.6 Lubricant
Optimization
of SBSE
Di-pentyl
phthalate
[131-18-0]
5.62 99.99 306.4 Plastizicer
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2.2.3 Sample Preparation, Extraction and Analytical Methods
The spiking standards were dissolved in ethanol at a concentration of 0.1 g/L. This solution
was used to prepare a stock solution by adding WfI, resulting in a final concentration of
0.05 mg/L. Two milliliters of this stock solution were mixed with 1 mL matrix sample and
further diluted with 2 mL WfI in a 20 mL glass vial. Therefore, 4 mL of the 5 mL are
WfI. The final solution contains 0.1 µg of each spiking substance, as well as 1 mL matrix
sample, leading to a spiking to sample ratio of 0.1 mg/L (i.e. 0.1 ppm contamination).
The high dilution with approximately 4 mL WfI was applied in order to reduce inhibitory
matrix effects [23]. Furthermore, linearity solutions were prepared from the same stock
solution of standards described above (concentration 0.1 g/L) diluting with WfI to 0.001,
0.005, 0.01, 0.05 and 0.1 mg/L for each spiking substance.
For the handling of the stir-bar, like depicted in Figure 2.2, the stir-bar was first exposed
to the solution for 1 h and stirred at 800 rpm at a temperature of 19◦C. Subsequently, to
the extraction step the stir-bar was rinsed with WfI, dried and placed in the sample holder
of the TDS for GC-MS analysis. The thermal desorption comprises the following four
steps: 1) On the TDS the splitless mode was selected and the stir-bar was rapidly heated
from 20◦C up to 300◦C at a rate of 60◦C/min. The final temperature was maintained
for 10 min. 2) The desorbed substances were transferred by a constant helium-flow at a
transfer temperature of 320◦C to the cold injection system (CIS). 3) The re-cryofocusing
occurs in a programmed temperature vaporizing (PTV) injector with a Tenax containing
liner at 0◦C. 4) Finally, the CIS temperature was ramped up to 300◦C at a rate of 8◦C/s
and was kept at the final temperature for 20 min. A solvent vent with a split vent purge
flow of 40 mL/min was selected for the transfer to the column. The initial separation
temperature in the column was 40◦C. After 2 min the temperature was ramped up to
300◦C at a rate of 10◦C/min under a constant carrier gas flow rate of 1.0 mL/min and
held for another 2 min at the final temperature. The mass spectrometric detection was
performed in scan mode for m/z values between 29 and 650 with the electron ionization
(EI) energy set to 70 eV. The MS transfer line and ion source temperatures were 300◦C and
230◦C, respectively. To evaluate the effectiveness of SBSE in pharmaceutical matrices, the
present study comprises three sets of experiments. The first set investigates the impact
of diverse parenteral drug products on the SBSE enrichment. The second set contains
experiments performed with a recently developed copolymer device [24] that was compared
to the established PDMS-stir-bar regarding its sorptive properties and sensitivity. The last
set contains experiments performed for optimization and with a simple and cost-effective
method to mitigate inhibitory effects for the detection of a broad range of leachable classes.
2.2.4 Effects of Drug Matrices on SBSE Recovery
Drug formulations are complex matrices and contain usually proteins as the active ingre-
dient, along with a system of inactive ingredients, the excipients, which are preservatives,
surfactants, tonicity modifiers, pH-buffers, stabilizers and bulking agents. In order to in-
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Figure 2.2: Scheme of the stir-bar handling in combination with TD-GC-MS analytic,
including adsorption, thermal desorption, cold injection trapping and subsequent gas chro-
matography and mass spectrometry analysis.
vestigate the effect of components of the complex matrices on the PDMS-coated stir-bar
sportive properties, four protein drugs (D: 1-4) along with four systems of their placebos
(P: 1-4) (formulations that contain excipients without the active ingredients) and four cor-
responding systems of single excipients (E: 1-4) (benzyl alcohol for product 1; polysorbate
80 for product 2; poloxamer 188 for product 3 and polysorbate 20 for product 4) were
examined. Table 2.2 lists the tested systems. For the four parenteral drugs the active
ingredient varied considerably in protein molar weight (40, 140, 145 and 150 kDa, for the
drug product 1, 2, 3, 4 respectively) and in concentration (0.1-30 mg). The four matrix
formulations, which were chosen to cover a broad range of formulations, were compared to
the corresponding placebo drugs in order to comparatively study the effect of the active
ingredients. To provide further insights, single excipients were compared to the correspond-
ing placebo formulations in order to show the impact of a single excipient on the sorptive
properties of the PDMS stir-bar. Blank measurements were performed using a conditioned
stir-bar subjected to WfI only. Additionally, reference measurements were performed where
the stir-bars were subjected to spiked WfI, i.e., WfI containing controlled amounts of sim-
ulated impurities. Relative recovery was defined as the change in response (peak area)
of the spiking substance in the drug product matrices compared to the response of the
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same spiking substance in pure WfI using the same extraction and quantification method.
The effect of proteins on SBSE recovery was statistically assessed using Student’s T-test.
Dependence between SBSE recovery, sensitivity and protein molar weight or concentration
was analyzed using Pearson’s correlation coefficient. Statistical significance was assessed
using F-statistics, and p-values below 0.05 were considered to be significant. To determine
the absolute recovery of the analytical instrument direct injection was conducted by in-
jecting the spiking substances into a glass wool prepared thermal desorption tube.
To study the effects of sample pH on the SBSE recovery, measurements of two drugs
(D: A-B) with extreme pH values were compared to a spiked water sample (pH = 7) (Table
2.2). The two drug products had pH values of 3.5 and 11.0, respectively. This covers the
range for all marketable acidic and alkaline injectables. For further verification of the
impact of an acidic and alkaline pH range without interacting excipient or drug molecules,
a phosphate buffer, a Tris buffer and an acetic acid buffer were also tested.
2.2.5 Quantitative Measurement and Limit of Detection
To obtain quantitative measurements, the linear range of the studied SBSE based analysis
was assessed by analyzing WfI, drug product 1, 2 and B (see Table 2.2) (n=4) containing
spiking solutions of THF-methacrylate and BHT-aldehyde at concentrations of 0.001, 0.005,
0.01, 0.05 and 0.1 µg/mL. Linear regression analysis was performed, and the correlation
coefficient (r2) as well as the precision (root-mean square deviation, RSD) were estimated
using Masshunter Quantitative Analysis (Gerstel GmbH, Mu¨lheim an der Ruhr, Germany).
The limits of detection (LOD) and quantification (LOQ) were calculated as the minimal
amount of analytes that results in a signal-to-noise-ratio (SNR) of 3 or 10, respectively.
Here, the SNR is defined as the peak height of the spiking substance and the baseline noise
adjacent to the peak including a range of 0.05 min before and after the peak. The noise
value for each noise range is computed as the standard deviation of the baseline over the
selected noise region. The SNRs were determined at four concentrations, and the results
were linearly interpolated. Confidence intervals were calculated using the fit residuals.
2.2.6 Different Stir-Bar Coatings
Recently, a new two-phase stir-bar coating with 5% ethylene glycol (EG) and 32 µL PDMS
(EG-PDMS, Gerstel GmbH) was proposed. Due to the polar nature of EG and its silox-
ane base, the extraction capability for both, polar and non-polar substances, is claimed
[20, 21, 22]. Additional substances spanning log KO/W from 1.80 to 13.12 and thus differ-
ences in polarity were used for our evaluation (Table 2.1). These substances, which can be
found as leachables, were 4-ethylphenol (log KO/W = 2.55), tris(2-butoxyethyl) phosphate
(log KO/W = 3.0), tetracosane (log KO/W = 13.12), THF-methacrylate and BHT-aldehyde
again. The main application of EG-PDMS stir-bars is the absorption of phenolic sub-
stances, like 4-ethylphenol [12, 25, 26]. The recovery and SNR were determined for each
substance and stir-bar coating as described above. Desorption- and analysis parameters
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Table 2.2: Drug products and placebo matrices used for the determination of the matrix
influence on the SBSE-recovery.
Matrix Protein
size
[kg/mol]
Special characteristic pH-
value
Surfactant
Drug product 1 ∼ 40 High content of benzyl alco-
hol (∼ 1.0%)
6.0 Polysorbate 80
Placebo product 1 - High content of benzyl alco-
hol
6.0 Polysorbate 80
Excipient 1 - Benzyl alcohol only - -
Drug product 2 ∼ 140 High content of sodium chlo-
ride (∼ 1.0%) and polysor-
bate 80 (∼ 0.07%)
6.5 Polysorbate 80
Placebo product 2 - High content of sodium chlo-
ride and polysorbate 80
6.5 Polysorbate 80
Excipient 2 - Polysorbate 80 only - Polysorbate 80
Drug product 3 ∼ 145 L-Histidin content 6.0 Poloxamer 188
Placebo product 3 - L-Histidin content 6.0 Poloxamer 188
Excipient 3 - Poloxamer 188 only - Poloxamer 188
Drug product 4 ∼ 150 High concentration of protein
(∼ 3%) and trehalose
5.5 Polysorbate 20
Placebo product 4 - High content of trehalose 5.5 Polysorbate 20
Excipient 4 - Polysorbate 20 only - Polysorbate 20
Drug product A - High content of salt; no pro-
tein
3.5 -
Acetic acid buffer - - 4.75 -
Phosphate buffer - - 6.0 -
Tris buffer - - 8.5 -
Drug product B ∼ 4.5 Polypeptide 10.8 -
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had to be adjusted for the EG-PDMS stir-bar due to the heat-sensitivity of the EG coating
(maximum temperature 220◦C).
2.2.7 Sample Preparation for SBSE in Alcoholic Solutions
To identify possible leachables in advance, extractable-studies are conducted under harsh
conditions to simulate worst-case scenarios. Regarding the USP recommendation for the
design of extractable-studies by the Draft <1663> [27], binary mixtures of miscible sol-
vents, such as alcohol/water mixtures have been utilized to simulate drug products with
a high polysorbate content. As SBSE is perfectly suited for aqueous solutions [11], the
extraction and concentration behaviour in solutions containing additional alcohol, like iso-
propanol (IPA), has to be evaluated. Therefore, SBSE was tested in an IPA/WfI (ratio
50/50) solution, spiked with THF-methacrylate and BHT-aldehyde, and compared to the
recovery observed in pure WfI. Further, the concentration behavior was evaluated by com-
paring the technique to the direct injection of the spiked IPA/WfI sample into a TD-GC-MS
system. For SBSE, 1 mL of the spiked sample was diluted with 4 mL WfI and stirred with
a PDMS coated stir-bar for 1 h prior to analysis. The direct injection was conducted by
injecting a sample volume of 5 µL into a glass wool prepared thermal desorption tube. The
two measuring methods only differed in a lower TDS rate of 20 ◦C/min as well as a lower
required CIS hold time of 10 min for the direct injection procedure.
2.2.8 SBSE Optimization
To mitigate inhibitory factors and to optimize SBSE sensitivity in drug products, we
tested different set-ups for enhancing the extraction procedure plus purposed an additional
preparation step of the stir-bar. Possible improvements were evaluated in form of the
optimal level of stirring speed and stirring time for the stir-bar, a simultaneous adsorption
by two stir-bars with different coatings and last a soaking procedure step of the stir-bar
prior to usage:
Stirring Optimum
In order to determine the variables time and speed affecting the SBSE extraction process,
the PDMS coated stir-bar was immersed in THF-methacrylate and di-pentyl phthalate
spiked WfI. The absorption of the stir-bar was tested at 500, 800, 1000 and 1300 rpm
within a stirring duration of 0.5, 1, 2 and 12 h.
Multi Stir-Bar
As each stir-bar coating is differently suited for the absorption of a specific polarity range
of substances, an approach to combine the extraction power of both was conducted [22].
While the plain PDMS coated stir-bar is stirring in the solution, the EG/PDMS coated
stir-bar is attached on the inner wall of the vial covered by the solution, like in Figure
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2.3 depicted. This enables a circulation of the sample around both stir-bars without a
steric hindrance of them. After the extraction procedure, both stir-bars were transferred
in a single desorption tube (Fig. 2.3) and were at the same time thermally extracted at
220◦C. Again, the study was carried out with a THF-methacrylate and di-pentyl phthalate
spiked WfI solution. The determined recoveries were compared to the absorption by a
single PDMS coated stir-bar.
Figure 2.3: Representation of the multi stir-bar handling of a PDMS and an EG/PDMS
coated stir-bar [22], including the simultaneously sample extraction and thermal desorp-
tion.
Soaking Procedure
Last, the improvement of the recovery by the PDMS stir-bar was tested in terms of a
soaking step. However, the stir-bar was stirred in pure WfI for an hour at room temperature
to soak the coating before application. The effect of a soaking preparation on SBSE
sensitivity was evaluated with the two spiking-substances, THF-methacrylate and BHT-
aldehyde, in water and in the matrices that showed the strongest inhibitory effects.
2.3 Results
2.3.1 Effects of Drug Matrices on SBSE
Figure 2.4 a) depicts representative chromatograms of a drug product, placebo and a WfI
reference measurement. The reference shows peaks corresponding to the location of the
spiking substances and additionally contamination caused by stir-bar bleeding. Additional
peaks in the placebo and drug chromatograms correspond to surfactant and trace amounts
of leachables. Absolute recovery of 55.7% and 88.6% was observed for THF-methacrylate
and BHT-aldehyde, respectively. The recovery from spiked protein drug matrices compared
to spiked protein-free placebo matrices and single excipients is displayed in Figure 2.4 b)
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for THF-methacrylate and c) for BHT-aldehyde. Exposure to either, the excipients (E),
the placebo (P) or drug product (D) caused a mild to decisive impact of SBSE-recovery,
depending on the distribution coefficient of the spiking substance (Table 2.3). The influence
of the active ingredient on the detection of the spiking substances was very low compared
to the placebo effect (4.5% vs. placebo effect). For most of the products the influence
of the active ingredient did not even exceed the standard deviation of the measurement
variability. Furthermore, no protein influence on the recovery of the spiking substances
was observed (p > 0.15) regardless of the protein’s molar weight or concentration applying
Pearson’s Correlation Coefficient (protein molar weight: r2 < 0.49; p > 0.29; protein
concentration: r2 < 0.81; p > 0.09).
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Placebos exhibited a more profound impact on the sorptive properties of the stir-bar.
A major influence in sensitivity was observed for the THF-methacrylate spiking, while
there were only minor effects caused by BHT-aldehyde. Recovery of THF-methacrylate
was most profoundly impaired by product 1 and the corresponding placebo (-72.8%), which
contained the preservative benzyl alcohol (not present in any of the other drug products).
These results were further substantiated by the analysis of another substance with a low
log KO/W -value, the 4-ethylphenol. Here we could prove the negative influence of the
benzyl alcohol. Further, the correlation to the distribution coefficient, as the recovery of
4-ethylphenol (-59.6%) was less influenced than the one of THF-methacrylate by benzyl
alcohol. Benzyl alcohol could be shown to be the dominant source of extraction inhibition,
whereas the other excipients, including the surfactants, exerted mild to moderate reduc-
tion of the THF-methacrylate recovery (polysorbate 80: -23.0%; polysorbate 20: -19.3%;
poloxamer 188: -4.5%) (Table 2.3).
The impact of the matrix’s pH on the SBSE of the three placebos and the two drug
products exhibiting the highest and lowest pH values is shown in Figure 2.5. A trend
of diminishing SBSE sensitivity was observed for matrices with a pH value substantially
different from a neutral pH (Table 2.3). For BHT-aldehyde the alkaline pH value caused
strong inhibition compared to an acidic pH value, as shown in Figure 2.5. Substantial
loss in reproducibility is also observed in the highly alkaline regime. The only increase
in recovery was observed for THF-methacrylate in product A, which is characterized by a
high salt content.
2.3.2 Quantitative Measurement and Limit of Detection
To evaluate the applicability of SBSE based analytics in drug matrices, the repeatability,
linearity, LOD and LOQ were investigated for three drug products compared to WfI. The
calibration plots were linear over the range of 0.005–0.1 µg/mL with correlation coeffi-
cients (r2) between 0.9920 and 0.9989 for both tested spiking substances (Table 2.3). The
LODs ranged from 2.2 to 2.8 µg/L and from 0.6 to 0.9 µg/L for THF-methacrylate and
BHT-aldehyde, respectively. LOQs reached values between 7.3 and 9.3 µg/L for THF-
methacrylate and between 2.1 and 3.3 µg/L for BHT-aldehyde.
2.3.3 Stir-bar Coating
Higher recovery and substantially increased SNR were achieved with the conventional
PDMS coating compared to EG/PDMS coating, as shown in Figure 2.6. For the polar
substance 4-ethylphenol, moderately higher recovery was achieved for the two phase coated
stir-bar, however at reduced values (18.0±3.4 vs 11.7±16.0). The PDMS stir-bar achieved
consistently higher recovery and up to 20-fold improvement in SNR in comparison to the
EG/PDMS stir-bar for all other tested substances/leachables, including the second polar
substance tested with log KO/W = 4.2 (Figure 2.6). The non-polar THF-methacrylate
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Figure 2.5: Influence of pH on the SBSE sorptive properties for THF-methacrylate and
BHT-aldehyde. The effect of pH is shown as the percentage change of recovery in the
pH samples (n=4 for acidic and neutral pH samples; n=7 for alkaline samples) versus a
pH-neutral water sample (n=4). The horizontal position of the bar pairs represents pH
values on the x-axis.
could not be detected with the polar EG/PDMS coated stir-bar, and detection of TBEP
was close to the noise level (SNR: 3.7±7.8).
2.3.4 Sample Preparation for SBSE in Alcoholic Solutions
The extraction and concentration behavior of SBSE was tested for an IPA/WfI sample
by comparing the recoveries to those observed within pure WfI. Further it was examined,
if the method was better suited than the direct injection for IPA/WfI solutions. The
negative influence of the alcohol on the uptake of the THF-methacrylate spiking, shown in
Table 2.4, is in accordance with the observed data of the drug product 1 matrix with its
benzyl alcohol content (see subsection 2.3.1). Nonetheless, SBSE still reached much better
recoveries for both spiking substances (Table 2.4) compared to the direct injection without
a sample preparation prior to GC-MS analysis.
2.3.5 SBSE Optimization
To achieve reduced LODs by optimizing the extraction procedure, different preparation
and handling steps of the stir-bar were tested.
30 2. Evaluation of Stir-Bar Sorptive Extraction coupled with TD-GC-MS
10
20
400
200
3
Figure 2.6: Sorptive properties of the PDMS phase compared to the EG-PDMS phase in
0.1 mg/L (ppm) spiked WfI. The detected peak area ratio and the corresponding SNR using
noise samples adjacent to the peaks of the five leachables 4-ethylphenol, THF-methacrylate,
Tris(2-butoxyethyl) phosphate, BHT-aldehyde and tetracosane (n=4).
Stirring Optimum
An important parameter affecting the extraction efficiency is the extraction time. For the
poorly absorbed spiking substance THF-methacrylate an extended extraction time resulted
in an increase in recovery (see Figure 2.7). In comparison, the extraction of di-pentyl phtha-
late spiking substance with an already high recovery of 95% did not impressively increase.
Contrary, a sticking to the PDMS-phase of the substance was observed, as artefacts were
detected in subsequent analysis of the same stir-bar. The recovery of both spikings during
the 12 h test-time was not significantly influenced by the stirring speed of the stir-bar.
Multi Stir-Bar
As already shown in subsection 2.3.3, the PDMS coated stir-bar is better suited for the
application of leachable-testing compared to the EG/PDMS coated stir-bar. The simulta-
neous multi-handling of both differently coated stir-bars and therefore the combination of
both optimum range applications was not possible. For both spiking substances, recoveries
below 5% were reached compared to the single application of a PDMS coated stir-bar.
2.3 Results 31
Table 2.4: Observed recoveries of the two spiking substances THF-methacrylate and BHT-
aldehyde affected by the IPA content. Comparison of the sample preparation step SBSE in
combination with GC-MS analytic to the direct injection without any sample preparation
for samples with IPA content.
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Soaking Procedure
The tested one hour soaking in WfI successfully increased the recovery by 14% – 22% for
spiking substances that showed inhibited recovery in matrices containing benzyl alcohol or
exhibiting a pH value of 8.5. Detailed results are given Table 2.5.
Table 2.5: Effect of soaking preparation on recovery of two spiking substances (THF-
methacrylate and BHT-aldehyde) in three matrices (WfI; Benzyl alcohol 5 mg/mL; Tris-
buffer pH-value = 8.5). Consistent increase is observed for recovery of THF-methacrylate
across all tested matrices. Recovery of BHT-aldehyde was successfully increased in the
presence of a Tris buffer, and remained unchanged in the other matrices.
WfI Benzyl alcohol matrix Tris buffer
THF-
methacrylate
BHT-
aldehyde
THF-
methacrylate
BHT-
aldehyde
THF-
methacrylate
BHT-
aldehyde
No
prepa-
ration
- - -71.5±1.5 -3.0±2 -11.5±0.5 -22.0±9.0
Soaking 14.5±5.5 1.0±3.0 -66.5±2.5 -2.5±8.5 -7.5±5.5 0.5±2.5
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Figure 2.7: SBSE stirring time and duration optimum for dipentyl phthalate and tetrahy-
drofurfuryl methacrylate.
2.4 Discussion
The present study evaluated the performance of SBSE in pharmaceutical applications.
The results suggest that SBSE can be highly valuable for the detection of leachables in
drugs with diverse formulations. Optimal sensitivity was obtained using PDSMS stir-bars
in the presence of matrices containing salts, stabilizer or proteins. The LOD of the PDMS
stir-bar even in the presence of inhibiting benzyl alcohol and alkaline pH values was still
in the ppb-range compared to the LOD reached by the direct injection. The influence of
the pharmaceutical matrix on the SBSE recovery could be further mitigated by soaking
the PDMS stir-bar in water prior to extraction.
Protein inhibition of PDMS extraction devices is a controversially discussed topic.
Whereas A. Oomen et al. [28] found no protein inhibition, fouling of the PDMS phase
by proteins was described by S. Ulrich et al. [19]. Both tested the influence of protein on
PDMS coated fibers. Our results regarding stir-bar extraction indicate that the concentra-
tion and the size of the proteins have a negligible impact on the system’s sensitivity. The
absence of protein fouling in our experiments is most likely caused by the constant motion
of the stir-bar, which reduces clogging by large proteins, and suggests good applicability
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as a sample preparation for drug matrix analysis. No major effect of the drug matrix was
observed on the recovery of BHT-aldehyde. Hence, sufficient uptake of substances with
unfavorable log KO/W appears to be achieved by reaching the thermodynamic equilibrium
between the drug matrices and the PDMS coating. Additionally, low inter-measurement
variability indicates high reproducibility of the partition equilibrium [13]. In contrast, the
recovery of THF-methacrylate (log KO/W < 3.6) shows some dependence on the product
matrix. Benzyl alcohol caused the most significant decrease in recovery. Benzyl alcohol
is a strong hydrogen bond donor and can bind to the PDMS absorbent phase, potentially
hampering the absorption of substances with a low partitioning coefficient. Addition-
ally, it influences the equilibration time of THF-methacrylate, which was shown to have a
prominent effect in a previous study with methanol [29, 30]. For compounds with low log
KO/W -values, the alcohol increases their solubility in the solution and therefore decreases
the partitioning into the PDMS phase. Our further results with 4-ethylphenol, however,
indicated comparable inhibition. Surfactants with diverse log KO/W values affect the re-
covery of analytes in the sample differently by changing the distribution coefficient. A mild
to moderate decrease of recovery was observed for high log KO/W polysorbate 80 whereas
recovery increased for low log KO/W poloxamer 188 as expected from Equation 1. How-
ever, product 2 with polysorbate 80 achieved better recovery for THF-methacrylate than
product 4 with polysorbate 20. This effect could be caused by the high salt concentration
of product 2, which leads to a salting-out-effect and fosters partitioning into the sampling
phase [29, 31]. Further, it was observed that product 3 improved the recovery. This might
be caused by deprotonation of THF-methacrylate by the bulking agent L-histidine.
The pH of the drug product is an important factor affecting the dissociation equilib-
rium in aqueous solutions and therefore the partitioning of leachables into the PDMS phase
[12]. Our results confirm that the non-ionic form yields maximum extraction efficiency, as
previously shown by Loconto et al. [17]. As the tested spiking substances both are weak
organic acids that can be deprotonated, a pH > pKa results in a decrease of the log KO/W -
value [32]. Therefore, an alkaline pH of 8.5 - 10.8 led to reduced binding of both spiking
substances to the absorbent phase of the stir-bar due to conversion to the dissociated form.
An acidic pH led to a recovery decrease only for THF-methacrylate due to its chemical
structure [33]. The increase of recovery of THF-methacrylate in the very acidic drug prod-
uct could be caused by the high concentration of the excipient sodium chloride in the drug,
which overcompensated for the negative effect of pH by increasing the log KO/W .
The use of different polymers in the absorbent phase of the stir-bar has been previously
proposed as a possible way to enhance the detection of polar and non-polar leachables
[22]. The dual-phase stir-bar EG/PDMS has the polar EG part [34], which enables spe-
cific binding by polar hydrogen bond donors by H-bonding [11, 20, 22]. However, due to
the heat sensitivity of the polar phase, this stir-bar cannot be exposed to high desorption
temperatures. Therefore, a broader detection profile of leachables is reached by the PDMS
stir-bar, as most leachables are desorbed from the absorbent phase at higher temperatures
[29]. Furthermore, higher phase bleeding of the sensitive EG phase led to a substantial
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decrease of the SNR. As a consequence, our results indicate that PDMS is to be preferred
over EG-PDMS for optimal sensitivity in a pharmaceutical matrix.
The limits of detection in the tested drug matrices are well below regulatory guide-
lines. SBSE was shown to be not only suited for leachable-studies with interferring drug
matrices but also for extractable-studies on the basis of solvent extracts, by concentrat-
ing analytes from a bigger sample volume, which can not be enabled by direct injection
[35]. Despite the inhibiting alcohol, SBSE enabled by concentrating of the analytes better
recoveries than without any sample preparation. Further, the SBSE technique was able
to measure quantitatively despite drug matrix effects. Nonetheless several methods of im-
proving SBSE recovery have been previously explored. As a first possibility to improve the
uptake of analytes with a low distribution coefficient, the addition of salt has been pro-
posed [25]. Furthermore, pH adjustment to a neutral value has been proposed for matrices
with extreme pH values [12]. However, these steps may not be applicable for complex
drug matrices in pharmaceutical manufacturing. As for product A with a salt content of
8 mg/mL, additional salt provides no improvement in recovery for THF-methacrylate. The
pH adjustment for product B is precluded in pharmaceutical experiments as it may lead
to protein degradation. Furthermore, both preparation steps only modify specific classes
of leachables in the sample while hampering the detection of others. For optimization
purposes, we tested the influence of the stirring time and the simultaneous application of
two stir-bars with different coatings. However, for some substances an increase of stirring
lead to a sticking to the coating of the stir-bar, which distorted following measurements
by artefacts. Although an application of multi stir-bars probably improves the absorption
of analytes, a decrease in recovery of the tested substances was observed, due to the al-
lowed low thermal extraction temperature for the EG/PDMS stir-bar. However, we have
successfully introduced a soaking step, which does not induce sensitivity bias across the
range of analytes of interest. The method is simple and fast to apply and has to be further
investigated in future studies.
2.5 Summary and Conclusion
SBSE is suitable for usage in pharmaceutical matrices due to its high sensitivity over a
wide range of chemical classes. No matrix inhibition by large protein drugs and only mild
reduction of recovery were observed in the relevant pH range. Limits of detection were
found to be well below the applicable thresholds in a worst case scenario analysis.
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Chapter 3
Extractable-studies of Single-Use
Systems
3.1 Introduction
The overall strategy of extractable and leachable testing follows a consecutive approach
[1, 2, 3]. Thereby, the primary purpose of extractables studies is to identify chemical
substances that may leach from process equipment into the contacting solution during
production, i.e. to provide qualitative data for the selection of target leachables [4, 5, 6].
In general, the extraction parameters, including the contact-solvent, time and temperature
are chosen to cover a wide range of conditions in order to maximize the recovery of potential
leachables than to simulate any individual product (Fig. 3.1).
Extractables
Unidentified
Overhead
Example
Extractables-Study #1
Example
Extractables-Study #
Figure 3.1: Correlation between extractable and leachable-data in dependence on the ap-
plied study design. (Top) Worst-case scenario: Possible occurring leachables are not totally
covered by extractable-footprints. (Bottom) Harsher extractable-study design: Leachables
are a subset of extractables.
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The purpose of the study was to create a comprehensive extractable data-set of a sterile
filter, which is applied in drug product processing, by using model solvents and conditions
that mimic harsh scenarios. The extracted analytes were subsequently analyzed with stir-
bar sorptive extraction (SBSE) in combination with gaschromatography mass spectrometry
(GC-MS), used for the detection of organic substances and for the identification of elemen-
tal impurities inductively coupled plasma (ICP)-MS analytic, respectively. According to
classical extractable testings USP <661.2> [7], the standard procedure involves incubation
of the drug product contact materials in polar solutions such as water or ethanol. In a
first class of experiments, the disposables were exposed to water solutions with different
pH-values for long time periods under heat-influence. In a second step, increased material
stress was induced by a more aggressive alcoholic contact solution. Direct injection of
the alcoholic sample into a thermal desorption tube prepared with glass wool with subse-
quent TD-GC-MS analytic was performed for the trade-off against slightly compromised
sensitivity, due to the small injection volume compared to the SBSE technique. Finally,
an unprepared material-sample of the disposable was directly exposed to thermal desorp-
tion. Compared to the pyrolysis technique, the applied temperature maximum for the
direct material thermal desorption was well below the melting point of the respective ma-
terial. However, increased amounts of extractables are expected to migrate out of the filter
with these kind of extractable study-design, which allows covering of all possible occurring
leachables. In a second part of the study, extractable-profiles of further single-use filters,
which differ in their material composition and manufacturer, were generated and compared
among each other regarding their extractable-output.
3.2 Materials and Methods
The main investigated piece of equipment, a Millipore Durapore Cartridge sterile filter,
designed for single-use, comprises the materials polyvinylidene fluoride (PVDF) as mem-
brane, polypropylene (PP) as supporting and finally silicone (SI) as sealing material. Fur-
ther tested filters included a filter with the exact same material composition and three
others with deviant polymers. The chosen filters which demonstrate the effect of a single
material change and the effect of the applied extraction-methods are listed in Table 3.1.
For the contact solutions, chemicals were purchased from the following providers: From
SigmaAldrich (Steinheim am Albuch, Germany) high purity NaOH, H3PO4, butylhydrox-
ytoluol (BHT) and n-eicosane were obtained. Absolute ethanol (99.7% optigrade, Pro-
mochem LGC, Wiesel, Germany), nitric acid, hydrocloric acid and isopropyl alcohol (IPA)
from VWR (Darmstadt, Germany) with a GC purity of 99.5% were used. Water for
Injection (WfI) was prepared on a Milli-Q Advantage A10 system (Merck GmbH, Darm-
stadt, Germany). Non-treated glass wool was purchased from SigmaAldrich and baked
out at 300◦C under helium flow for 30 min prior to use. For ICP measurements an ICP
multi-element standard solution was purchased from AccuStandard (AccuStandard Eu-
rope, Switzerland).
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Table 3.1: Description and material-composition (1: Filter membrane; 2: Housing mate-
rial; 3: Seal material) of the investigated filters with the applied extracting agents and
conditions. Abbreviations: Polyvinylidene fluoride (PVDF); Polypropylene (PP); Silicone
(SI); Polysulfone (PSU); Mixed cellulose esters (MCE); Nylon (with an embedded base
material of polyester fleece).
Nr. Filter Equipment
composi-
tion
Extraction method
WfI - pH Isopropyl
/WfI
Thermal
Desorp-
tion
< 3 approx. 7 > 9.5
1 Millipore Dura-
pore Cartridge
1: PVDF;
2: PP;
3: SI;
x x x x x
2 Millipore Opticap
XLT 10 Capsule
0.22 µm
1: PVDF;
2: PP;
3: SI;
x
3 Millipore Opticap
XLT 10 Capsule
1.2 µm
1: MCE;
2: PP;
3: SI;
x
4 Millipore Millidisk
20 Cartridge
1: PVDF;
2: PSU;
3: SI;
x x x x
5 Pall Ultipor N66
Cartridge
1: Nylon;
2: PP;
3: SI;
x
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3.2.1 Sample Preparation
As the disposable filter is intended for the application of different drug product fillings, the
study was performed with diverse extract solutions in harsh conditions. For this purpose
the filter was analyzed in contact with water with different pH values for an incubation
time of 3 days at a temperature of 95◦C. Moreover, an IPA/water mixture was tested as a
more aggressive solvent-mix at a temperature of 75◦C. The incubation for all static extrac-
tions was carried out in the dark for three days. Lastly, to further increase the material
stress, the filter materials were directly subjected to thermal desorption for 10 min at 150◦C.
For the preparation of the stock solution of NaOH, approximately 800 mg of sodium
hydroxide was given in a 20 mL volumetric flask and dissolved in WfI (eq. 1000 mmol/L).
Subsequently, 1.0 mL of this solution was diluted to volume with WfI in a 10 mL volumet-
ric flask (eq. 100 mmol/L). Again, 1.0 mL of the resulting solution was diluted to volume
with WfI in a 100 mL volumetric flask (eq. 1 mmol/L). In turn for the stock solution of
H3PO4, approximately 2.31 g of phosphoric acid were given in a 20 mL volumetric flask
and dissolved in WfI (eq. 1000 mmol/L). The same dilution steps as used for the stock
solution of NaOH were applied to reach a concentration of 1 mmol/L. Last, WfI and iso-
propyl alcohol with a ratio of 1/1 were prepared.
Before extraction, the filters were autoclaved for 30 min at 123◦C. Afterwards the
filters were incubated according to the extracting conditions described above (see Table
3.1). The filters, without housing were placed into closeable glass flasks and covered with
the particular solvents as depicted in Figure 3.2. Additionally, for the preparation of
the blank solution, 25 ml of WfI and of the IPA/WfI mixture were placed separately in
Erlenmeyer glass flasks, which were closed with ground glass stoppers. According to the
different solvents and their boiling points, the filters as well as the blank solutions were
incubated at the particular temperature in the dark for three days. After incubation, the
samples were cooled down to room temperature and decanted into glass vials for TD-GC-
MS measurements. For the ICP-MS detection the samples were stored in polystyrene tubes
to avoid absorbing glass contact.
3.2.2 Extractable Screening - SBSE TD-GC-MS
The PDMS coated stir-bar was exposed to 5 mL of the sample for 1 h and stirred with
800 rpm at 19◦C. Following the extraction step, the stir-bar was rinsed with WfI, dried by
dabbing and placed in the autosampler (TDS A2, Gerstel GmbH). Blank measurements
were performed by immersing a stir-bar in pure WfI, to determine the system contamination
by estimating the background noise. Reference measurements were done with stir-bars
subjected to n-eicosane spiked WfI and measured at the beginning and at the end of
the injection sequence. N-eicosane, a long chain saturated aliphatic hydrocarbon with a
molecular mass of 282 g/mol, was chosen as a spiking substance, due to its late eluting time-
point at the end of the chromatographic separation and thus allowed semi-quantification.
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Figure 3.2: (Left) Filter preparation: Filter with housing filled with the extraction medium
and sealed with steel clamps. (Right) Filters without housing placed in glass flasks and
covered with the respective extraction medium.
Because of its low volatility the compound’s response factor can be used as the lower limit
of quantification. By semi-quantifying with aforementioned spiking substance, a worst-
case quantity calculation of the extractables was carried out. It is used to demonstrate
that the method/system is suitability for extractables with a higher boiling point (higher
molecular mass and higher retention time). The spiking standard was dispersed in ethanol
with the help of sonication at a concentration of 0.1 g/L and diluted with WfI to simulate
a 0.1 ppm (0.05 µg/mL) concentration. The extraction of (semi-)volatile substances was
performed using a thermal desorption (TD) system (TDS 3, Gerstel GmbH) equipped
with a multi-purpose autosampler. During the extraction-process, volatilized analytes were
purged under helium-flow into the precooled cold injection system (CIS, Gerstel GmbH),
concentrating the extracted compounds in the inlet for subsequent GC-MS analysis. A
detailed list of all operating parameters is provided in chapter chapter 2. Extractables with
concentrations above 0.01 ppm were further characterized. Mass spectra of all compounds
were matched with the NIST library 2.0 [8]. In case of no match the m/z spectrum was
analyzed manually using the proprietary, internal databases of the Roche GmbH.
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3.2.3 Extractable Screening - TD-GC-MS
Using a microliter syringe, 30 µL of the IPA/WfI sample and the pertaining blank solu-
tion were given into preconditioned, glass-wool prepared thermo desorption tubes (Gerstel
GmbH). Reference measurements were performed by injecting n-eicosane on a 0.1 ppm
level. Therefore, n-eicosane was dispersed in IPA and diluted with WfI to simulate a 1/1
ratio. The tubes were transferred into the autosampler and directly analyzed. Operating
parameters were identical to the stir-bar analysis except the CIS setting in order to avoid
icing of the WfI in the CIS system. Therefore, the applied initial CIS temperature was
set to 20◦C instead of 0◦C. Again, only extractables with concentrations above 0.01 ppm
were further characterized. Mass spectra of all compounds were matched with the NIST
library 2.0 [8]. In case of no match the m/z spectrum was analyzed manually using the
proprietary, internal databases of the Roche GmbH.
3.2.4 Extractable Screening - Direct TD-GC-MS
For the direct thermal desorption, ∼15 mg of both main polymer materials of the filters
were taken and examined. The sample pieces were placed in preconditioned tubes and
exposed to thermal extraction at a temperature of 150◦C with a hold-time of 10 min (TDS
rate: 60◦C/min). Reference measurements were provided by simulating a 15 mg material-
piece with an incorporated additive, by injecting BHT in a prepared glass wool tube with
a concentration of 0.1 ppm [9]. For the analysis of the extractables, only substances with
a semi-quantified concentration above 0.01 ppm were further analyzed. Mass spectra of
all compounds were matched with the NIST library 2.0 [8]. In case of no match the m/z
spectrum again was analyzed tentatively using the proprietary, internal databases of the
Roche GmbH.
3.2.5 Extractable Screening - ICP-MS
The two WfI extract-samples obtained at low and high pH were used for the detection of
elemental impurities. It is recommended to test for elements, which are known to impact
product quality/stability. Therefore, a quantitative screening for inorganic extractables
was performed by ICP-MS (Agilent 7700x) for the following elements: Ag, As, Au, Ba,
Cd, Co, Cr, Cu, Hg, Ir, Li, Mo, Ni, Pb, Pd, Pt, Rh, Ru, Sb, Se, Sn, Tl, V. Further elements
listed in the ICH Q3D Elemental Impurities guideline are Ti, W, Zn, Zr, Ca, Fe and Al
[10] and were tested. As reference substances a set of typical elements was used in order to
confirm the system suitability. The standard spiking elements were the following: Bi, Ge,
In, Li6, Sc, Tb, V and Hg with a concentration of 10 µg/mL each. The standard solution
was then diluted to reach a concentration of 1 µg/mL. Triple blank measurements were
prepared in 50 mL plastic tubes with matrix solution, containing a 3% HNO3 and 1% HCl
solution. For the autosampler, a rinsing solution of 5% HNO3 and 1% HCl was prepared,
which was applied 60 sec after each sample with a rinse speed (nebulizer pump) of 0.1 rps.
Each sample was measured twice, with and without spiking. For the spiked samples 25 µL
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of the standard solution (1 µg/mL) were transferred into a 15 mL tube and completed to
5 mL with the sample. The ICP run parameters of the nebulizer pump (Micro mist) were
configured at 0.3 rps with an uptake time of 60 sec and a stabilization time of 30 sec. For
the MS a He gas-flow rate of 5.0 mL/min was adjusted.
3.3 Results
3.3.1 Evaluation of the Extraction Techniques
Table 3.2 summarizes all detected extractables, extracted from the disposable filter Nr. 1,
Millipore Durapore Cartridge, and their concentrations depending on the applied extrac-
tion technique. Static extraction based on water with different pH-values was shown to re-
lease only small amounts of extractables with a concentration above 0.01 ppm. Higher con-
centrations plus different substances were observed in the static extraction, using IPA/WfI
extract. However, highest concentrations of extratables were extracted in the direct ma-
terial thermal stress testing compared to the other tested extraction methods. It can be
concluded, that substances with concentrations above 1 ppm, identified by direct mate-
rial thermal desorption, were also found with other extraction methods with lower stress-
levels on the polymer-material, including the substance 9,9-bis(methoxymethyl)fluorene.
Furthermore, it can be observed that with different extraction techniques, different sub-
stances were extracted. With the IPA/WfI mixture the extracted substances display
lower polarities, compared to the pure water extract solution. By the use of direct mate-
rial thermal extraction, non-fragmented substances were determined, such as 2,6-bis(1,1-
dimethylethyl)-2,5-cyclohexadiene-1,4-dione and adipic acid, di(but-2-en-1-yl) ester. The
corresponding fragments 2,6-di-tert-butyl-4-methylene-2,5-cyclohexadienone and (E)hex-4-
enyl,4-hydroxybutanoate were extracted with the other methods. Additionally, substances
that were only determined by direct material thermal extraction were the very volatile
R-(-)-1,2-propanediol and the non-polar caprolactam. The different pH-values of the water
extracts did not have a major impact. With ICP-MS analysis no non-organic extractables
were identified for the investigated single-use filter.
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3.3.2 Different Single-Use Filters
The effect of different filter materials on the extractable spectrum is displayed in Table
4.12. Comparing the extractable-profile of filter 1 (Millipore Durapore Cartridge - see
table 3.2) to filter 2 (Millipore Opticap XLT 10 Capsule 0.22 µm - see table 4.12), which
comprised both the same material compositions, showed similar extractable-profiles.
In contrast, filter 3 (Millipore Opticap XLT 10 Capsule 1.2 µm) uses a mixed cellulose
ester (MCE) as filtration membrane rather than PVDF as for filter 1. The PP housing
of filter 3 is much smaller and provides therefore much less material in contact to the
extracting solution than filter 1. For filter 3 only one extractable, namely the 2,6-di-tert-
butyl-4-methylene-2,5-cyclohexadienone was detected, which was also observed in case of
filter 1.
Although filter 1 and filter 4 (Millipore Millidisk 20 Cartridge) differed only in the hous-
ing material, no single matching extractable was observed for both filters. For the latter
filter, the substance 1,1-(1-methylethylidene)bis[methoxy-benzene was detected, which is a
classical building block of the polymer polysulfone (PSU) [11]. Further, the antioxidant di-
ethyl phthalate was found, which functions as a protector for the vulnerable PSU-material.
In case of the last filter (Pall Ultipor N66 Cartridge) from a different manufacturer and de-
vice material (nylon with an embedded base material of polyester fleece) no corresponding
extractables with the extractable-profile of filter 1 were found. As expected, nylon building
blocks were extracted, including 1-(3,5-di-tert-butylphenyl)ethanone and polyester polyol.
Beside the organic extractable examination, the filters were tested for inorganic addi-
tives with ICP-MS analytic. A single elemental impurity, namely antimony (Sb), which is
classically used as fire retardant for diverse polymers [12], was determined for the Millipore
Opticap XLT 10 Capsule 1,2 µm and Pall Ultipor N66 Cartridge filter with a concentration
of 2.1 mg/L and 2.2 mg/L, respectively.
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3.4 Discussion
In the previous chapter, SBSE was shown to be the gold standard method for the detec-
tion of leachables in drug product matrices. A similar setup can be used for an extractable
study. Hereby, we found direct injection of single-use material probes into a TDS to be
more useful as an initial, quick-shot analysis. While the range of compounds and com-
pound groups which are detected in direct material thermal desorption experiments are
quite similar to those extracted with an organic solvent-mix from polymeric materials,
the concentrations and fragments are much higher and larger, respectively. No impact of
water extract pH-value was observed, as the level of extraction was mostly driven by the
incubation temperature of 100◦C. Subsequent studies in accordance with USP <661> can
then be employed to fully characterize the material for the application of different drug
products [7]. In summary the three analysis methods offer very different levels of material
stress, with water solution being the most benign and direct material desorption the most
aggressive one.
Importantly we found that a single material change e.g. in the housing in the composi-
tion of a polymer-mix of a SUS, can heavily influence the extractable-outcome. Although
a material-change from the inert material PVDF to a non-classical polymer material such
as MCU does not have an impact on the organic extractable-outcome, it can alter the
inorganic impurity level. Therefore, extractable-studies on the SUS are indispensable prior
to the leachable-study itself. Nonetheless, it was also shown that SUSs with the same ma-
terial composition yield comparable extractable-footprints. However, the overall number
of extractables from the filters was low.
3.5 Conclusion
In summary it was shown that direct material TD stress testing can be a time saving first
step, as it does not require any sample preparation nor solvents, that may contaminate
the sample. However, for a comprehensive evaluation multiple and complementary stress
tests should be performed to fully characterize a disposable and to allow for subsequent
leachable analysis. Nonetheless, before any extraction of a new SUS is conducted, already
performed studies of different SUSs, but with the same polymer-mixes, should be consulted
in order to point out possible extractables in advance and thus allow target analysis.
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Chapter 4
Studies on Leachables in commercial
scale Protein Drug Filling Lines
Parts of the following chapter are published in the International Journal of Pharma-
ceutics, titeled “New Studies on Leachables in commercial scale Protein Drug Filling
Lines using Stir Bar Sorptive Extraction coupled with TD-GC-MS and UPLC/QTOF-
MS/MS analytics” [1]
The increasing application of Single-Use Systems (SUSs) in pharmaceutical manufacturing
lines poses a potential risk of polymer-related impurities leaching into the process stream
and persisting through the manufacturing process. To minimize any potential toxicity
and impairment to the product’s quality, safety thresholds are strictly regulated and en-
forced in particular for parenteral solutions. At present, impurities are estimated from
extractable profiles, which are generated for each SUS with thermal or static extraction.
In this study we employed target leachable-testing by taking samples directly from an
industrial filling line probed during real-life processing of three parenteral drugs (n=2)
under actual process-conditions, to estimate the concentration of leachables throughout
drug-manufacturing. At five different points, samples were drawn to study the individual
impact of SUSs on the leachable accumulation within the drug-filling process. The drug
products were examined for leachables using stir-bar-sorptive-extraction (SBSE) with poly-
dimethylsiloxane (PDMS) and ethylene glycol (EG)-PDMS coated stir-bars. Subsequent
extraction from the stir-bars and analysis of the substances was performed with TD-GC-MS
and solvent-back-extraction (SBE)-UPLC/QTOF-MS/MS analytics. Our study revealed
the following main results: 1) Leachables were found in extremely low concentrations, all
below toxicological thresholds (highest leachable concentration in the final drug product 1
(DP1): 0.274 ppm < drug specific threshold: 6.0 ppm; DP2: 0.010 ppm < 0.2 ppm; DP3:
0.011 ppm < 0.5 ppm). All compounds identified in the leachables study were found to
be non-genotoxic. 2) Most of the leachables (68%) that were found were already observed
at the beginning of the filling process, delivered by the API Neither a common source
of leaching could be identified within the filling-line nor a specific product influence on
quality or quantity of leachables. 3) No leachable increase could be observed over the
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filling process. On the contrary leachable concentrations declined with 83%, which was
partly due to dilution by buffer-feed and to a proven absorption of leachables by filters and
silicon tubing. 4) No active ingredient influence on the leachable-outcome was observed
by placebo to drug product comparison. In contrast, the pH-setting of the drug product
influenced the leaching-behavior to the greatest possible extent.
Cryo-
Mixing- Filtration-
Filter cartridges
Vials
Sampling
Sampling
Sampling
Sampling
Sampling
Buffer-bag
Thawing-set
Transfer-tube
Filling-
tube
Figure 4.1: Graphical abstract of a filling line equipped with diverse Single-Use Systems:
Major reduction in concentration of leachables during the filling process.
4.1 Introduction
Single-Use Systems (SUSs), including silicone tubing, filter cartridges and formulation bags
with diverse polymeric materials, recently emerged as the material of choice for various
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pharmaceutical production lines [2, 3, 4]. However, an abundance of polymeric surfaces
with direct or indirect contact to the product in filling lines poses a risk of contaminating
the final product and to impair its quality. Hence, SUSs are subject to multiple regulations
including USP (<665> review stage, <1665>) and FDA (US 21 CFR 211.65) specifying
the evaluation of their compatibility with the drug formulation [5, 6, 7]. This includes test-
ing for potential leaching of functional additives (e.g. antioxidants and plasticizers). These
tests are performed before the actual usage and simulate worst case scenarios to identify
extractable substances by exposing the material to appropriate solvents under exaggerated
conditions of temperature and time [8, 9, 10, 11]. However, this kind of testing does not
identify or quantify the exact amount of individual leachables, as observed in real-life pro-
cessing. Although extractables can be considered as potential leachables, not all extracta-
bles leach into drug products. In addition, drug formulation components or buffers may
interact with SUSs in various ways and form leachables that were not previously identified
during extractable analysis with solvents [12, 13, 14, 15]. The risk of residual leachables,
beyond detection in extractable studies, is particularly pronounced in injectable solutions
compared to other dosage forms, as with this route of administration toxic substances can
be most harmful [16]. As leachables may be of genotoxic concern, international safety
regulations (ICH M7) have set an acceptable daily intake dose (ADI) concept derived from
the maximum lifetime drug treatment days [17, 18]. Therefore, leachable studies of the
whole filling process are highly warranted in addition to the extractable-profiles of each
SUS, to elucidate the actual leachable exposure and to ensure the patient’s safety and the
product’s integrity.
The quantification of leachables poses several requirements on the measurement tech-
nique and the sample preparation [19, 20]: 1) Sufficient sensitivity over a broad spectrum
of substances. 2) Avoidance of plastic parts in the analysis, including e.g. Eppendorf-
tubes. 3) Minimizing interference of drug components with the analysis, such as protein
clogging in columns. To meet these requirements stir-bar sorptive extraction (SBSE) was
recently introduced in combination with high performance liquid chromatography (UPLC)
and gas chromatography (GC) for detection of non-volatile and semi-volatile leachables in
drug matrices [21, 22, 23, 24]. This solvent-less sample enrichment technique allows di-
rect extraction of solutes from aqueous matrices and works well in the presence of protein
drugs. In SBSE, a glass-lined magnetic stir-bar, coated with either a polydimethylsiloxane
(PDMS) or a polar ethylene glycol (EG)-PDMS copolymer layer, is immersed into the
sample [25]. After sufficient stirring with the bar, analyte partition equilibrium is reached
on the coating. The recovery of substances is based on each analyte’s octanol/water distri-
bution coefficient (KO/W ) and the phase ratio between the aqueous drug sample and the
coating of the stir-bar. GC- and UPLC-mass spectrometry (MS) analysis of the stir bar
can then be performed by transferring the analytes into the system via thermal desorption
(TD) and solvent back extraction (SBE), respectively.
The purpose of this study was to identify and quantify accumulation of leachables in
real-world commercial scale industrial drug-filling lines for protein drug products in order
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to shed light on the actual patient exposure. To understand the accumulation of leachables
in the final drug formulation it was indispensable to outline the leachable-concentrations
within the drug manufacturing over different processing steps, like the buffer fed-in or
the purification-steps, beyond extractables-studies [26]. For the first time actual leachable
results were published beside the designing and implementing requirements [20, 27, 28].
Therefore, samples of several injectable drug formulations, representative of a typical phar-
maceutical production portfolio, were drawn during the actual filling process after contact
with a SUS at five points under actual commercial scale production conditions. Leachables
were traced back to their origin (SUS) by identifying the first point of appearance in the
filling line and by comparing them to previously obtained extractable-footprints of each
SUS. This was studied for multiple product formulations. Our study also includes the
filling tube, which is subjected to mechanic stress and poses an elevated risk, as no further
purification or filtration step follows the surface contact to this SUS [29]. Furthermore,
filters, with their large contact surfaces, and the buffer bag, used for the preparation of the
buffer, with its material mix and long contact time to the buffer-solution were expected to
be particularly relevant. Further the extraction-power of pH-setting of the drug product
and its active ingredient, the protein, during the filling process in contact to SUSs was
investigated. Therefore, we tested different drug products with diverse pH-settings and
further compared a placebo-run with its pertaining drug product-run. Finally, the impact
on patient’s safety was classified by evaluating the amount, toxicity and carcinogenicity of
the detected substances.
4.2 Materials and Methods
4.2.1 Chemicals
To assess the exposure to leachables from modern drug filling lines, five commonly used
SUSs (Table 4.1) with large contact surfaces were studied for polymer related impurities.
The potential leachable-footprint can vary substantially between the tested SUSs, due to
differences in material compositions, compounded additives and fabrication. All tested
SUSs were certified as USP class VI biocompatible. Samples were drawn from a filling line
comprising the listed SUSs during processing of three parenteral drugs (Roche Diagnostic
GmbH, Mannheim, Germany), which were selected to be representative of a pharmaceuti-
cal manufacturer’s portfolio (Table 4.2).
Sample analysis was performed with GC and UPLC. Nine spiking substances were
added to allow semi-quantitative evaluation of the GC and UPLC analysis. The substances
were selected because they are commonly observed as typical leachables. Substances that
are commonly observed as leachables in pharmaceutical processing [29] were purchased from
Sigma Aldrich (Steinheim am Albuch, Germany) with purity > 97%. For GC analytic:
Tetrahydrofurfuryl (THF) methacrylate log KO/W 1.8; Di-ethyl-phthalate log KO/W 2.45;
3,5-Di-tert-butyl-4-hydroxybenz(BHT)-aldehyde log KO/W 4.2 and Butylated hydroxyl-
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toluene (BHT) log KO/W 5.3. UPLC analytic, positive ionization-mode: 2-(2-hydroxy-5-
methyl-phenyl)benzotriazole (UVA P) log KO/W 6.1; 2-(2H-Benzotriazol-2-yl)-4,6-bis(1,1-
dimethylpropyl)phenol (Tinuvin 328) log KO/W 7.25; 2,5-Bis(5-tert-butyl-benzoxazol-2-
yl)thiophene (Uvitex OB) log KO/W 8.0; Tris(2,4-Di-tert-butylphenyl)phosphite (Irgafos
168) log KO/W 15.5; UPLC analytic, negative ionization-mode: Pentaerythritol tetrakis(3-
(3,5-di-tert-butyl-4-hydroxyphenyl)propionate) (Irganox 1010) log KO/W 19.4. Water for
Injection (WfI) was prepared on a Milli-Q Advantage A10 system (Merck GmbH, Darm-
stadt, Germany). Absolute ethanol (99.7% optigrade, Promochem LGC, Wiesel, Ger-
many), methanol (UPLC-grade, Biosolve, Dieuze, France) and ethyl acetate (99.8% Sigma
Aldrich) were applied as solvents and/or eluents. Formic acid (Sigma Aldrich) was used
for LC ion suppression and non-treated glass wool (Sigma Aldrich) for direct TD spiking
application.
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4.2.2 Extractables
Extractable footprints were obtained in order to restrict the possible leachables for each
SUS, and to enable association of different substances with source SUSs in the leachable
study. Best practice recommendations and compendial standards for extractables and
leachables note that a leachables-extractables correlation, either qualitative or quantita-
tive, should be established by linking actual drug product leachables with extractables
from corresponding controlled extraction studies performed on each SUSs. The flowchart
(Figure 4.3) depicts the overall strategy of the semi-quantified leachable-testing approach
based on toxicological extractable profiling and other analytical techniques. Extractable-
testing was performed by exposing the polymer component to appropriate solvents at high
temperatures to detect potentially toxic additives that might leach into the drug prod-
uct. The considered SUSs were in the same condition (e.g. gamma sterilized) as those
integrated in the actual filling line for the leachable-testing. No water flush step prior to
testing was performed, in order to prevent a possible loss of extractables. For the detec-
tion of (semi)-volatile extractables all SUS materials were analyzed with direct TD with
subsequent GC-MS (7890B GC-System, equipped with a DB-1ms column, 5977A MSD,
Agilent Technologies, Waldbronn, Germany), to minimize sample preparation and elimi-
nate sample contamination from the solvents. This extraction procedure was previously
shown to provide a comprehensive list of leachable candidates [31, 32]. Conventional static
extraction with a solvent-mix under heat-influence was performed to yield substances with
higher polarity and molecular weight, as well as non-volatile substances. These were subse-
quently analyzed by UPLC (Acquity, Waters GmbH, Eschborn, Germany) combined with
electron spray ionization (ESI) and MS/MS analysis (Xevo G2-S Tof, Waters GmbH).
GC-MS Measurement of (Semi)-Volatile Extractables
For the direct TD, ∼15 mg of each SUS material was taken and examined. The sample
pieces were placed in preconditioned tubes (Gerstel GmbH, Mu¨lheim an der Ruhr, Ger-
many) and exposed to thermal extraction at a temperature of 150◦C with a hold-time
of 10 min (rate: 60◦C/min). The extraction of (semi-)volatile substances was performed
using a thermal desorption system equipped with a multi-purpose autosampler (TD 3 and
TD A2, Gerstel GmbH). During the extraction-process, volatilized analytes were purged
under helium-flow into the precooled (-50◦C) cold-injection-system (CIS, Gerstel GmbH),
concentrating the extracted compounds in the inlet for subsequent GC-MS analysis (heat
program: 40°C for 2 min – rate 10◦C/min – 320◦C for 10 min). A detailed list of all operat-
ing parameters is provided in Table 4.3. The compounds were identified in the extraction
study by comparing the chromatograms to a blank analysis of an empty analytical tube.
Reference measurements were provided using a BHT prepared glass wool tube with a con-
centration simulating a 0.1 ppm contamination of a 15 mg material-piece. Mass spectra
(scan range 33-650 m/z) of all compounds were matched with the NIST library 2.0 [33].
In case of no match the m/z spectrum was analyzed manual using proprietary, internal
databases of the Roche GmbH.
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Table 4.2: Tested drug product formulations and their individual analytical evaluation
threshold (AET) regulated by the ICH M7 guideline for single and multiple impurities, as
well as the contact to the individual SUSs are listed.
Drug
Product
Formulation-
Characterization
AET [ppm]
for single
impurities
[17]
AET [ppm]
for multiple
impurities
[17]
Contact to SUSs
Drug
Product 1
Protein size: ∼140
kg/mol; High content
of sodium chloride
(∼1.0%) and polysor-
bate 80 (∼0.07%)
6.0 6.0 Thawing tubing;
Transfer tubing; Bag
in combination with
filter; 2 x Filters;
Filling tubing
Drug
Product 2
Protein size: ∼1
kg/mol (∼0.7%); Phos-
phate based buffered
with a high content of
trehalose (∼6%)
0.2 0.6 Thawing tubing;
Transfer tubing;
Bag; 2 x Filters;
Filling tubing
Drug
Product 3
Protein size: ∼150
kg/mol; High con-
centration of protein
(∼3%) and trehalose;
Polysorbate 20
0.5 1.5 Thawing tubing;
Transfer tubing; 3
x Filters; Filling
tubing
Drug
Product 4
Protein size: ∼150
kg/mol; High content
of L-Histidine; Polox-
amer 188
0.5 1.5 Thawing tubing;
Transfer tubing; 2
x Filters; Filling
tubing
Placebo
Product 4
High content of L-
Histidine; Poloxamer
188
0.5 1.5 Bag; 2 x Filters; Fill-
ing tubing
Drug
Product 5
pH: ∼3.5; High content
of sodium chlorid
20 20 Thawing tubing;
Transfer tubing;
Filter; Filling tubing
Drug
Product 6
Protein size: ∼150
kg/mol; pH: ∼6.0;
Polysorbate 20
12 12 Thawing tubing;
Transfer tubing;
Filter; Filling tubing
Drug
Product 7
Protein size: ∼30
kg/mol; pH: ∼7.5;
Polysorbate 20
2.5 7.5 Thawing tubing;
Transfer tubing;
Filter; Filling tubing
Drug
Product 8
pH: Sodium carbonate
and mannitol ∼10.0;
0.75 2.25 Thawing tubing;
Transfer tubing;
Filter; Filling tubing
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Figure 4.2: Strategy for toxicological risk-based leachable-testing based on extractable-
footprints.
Table 4.3: Operating parameters: A) TDS, CIS, GC and MS parameters for the thermal
extraction study. B) TDS, CIS, GC and MS parameters for the leachable-study. C) UPLC
and QTOF-MS/MS parameters for the extractable- and leachable-study.
A) Method: TD-GC-MS
Extractable-Study
GERSTEL TDS
B) Method: TD-GC-MS
Leachable-Study
GERSTEL TDS
C) Method: UPLC/GTOF-MS
Extractable/Leachable-Study
Waters UPLC
TDS Setting TDS Setting
Temperature Program Temperature Program
Initial
Tempera-
ture
20◦C Initial
Tempera-
ture
20◦C
Delay Time 3.00 min Delay Time 3.00 min
Rate 60.0
◦C/min
Rate 60.0
◦C/min
End Temp. 150◦C End Temp. 300◦C
Hold Time 10.0min Hold Time 10.0min
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Transfer
Temp:
320◦C Transfer
Temp:
320◦C
Desorption
Mode:
Splitless Desorption
Mode:
Splitless
CIS Setting CIS Setting
Liner type
with glass
packed
wool
Liner type
with glass
packed
wool
Mode: Solvent
Vent
Mode: Solvent
Vent
Total Flow: 40.5
mL/min
Total Flow: 40.5
mL/min
Vent Pres-
sure:
49 kPa un-
til 0.01 min
Vent Pres-
sure:
49 kPa un-
til 0.01 min
Purge Flow
to Split
Vent:
36.5
mL/min at
1.51 min
Purge Flow
to Split
Vent:
36.5
mL/min at
1.51 min
Temperature Program Temperature Program
Initial
Temp.:
-50◦C Initial
Temp.:
-20◦C
Equilibration
Time:
0.50 min Equilibration
Time:
0.50 min
Initial
Time:
0.10 min Initial
Time:
0.10 min
Rate: 8.00◦C/s Rate: 8.00◦C/s
End Temp: 300◦C End Temp: 300◦C
Hold Time: 20.00 min Hold Time: 20.00 min
GC Setting GC Setting UPLC Setting
Column
Agilent
122-0132:
A002
Column
Agilent
122-0132:
A002
Column
Agilent
InfinityLab
Poroshell 120
DB-1ms: 30 m x 250
µm x 0.25
µm
DB-1ms: 30 m x 250
µm x 0.25
µm
HPH C8: 2.1 x 50 mm
2.7 µm
He Column
Flow:
1 mL/min He Column
Flow:
1 mL/min Column
Flow:
350 µL/min
Temperature Program Temperature Program Temperature Program
Initial
Temp.:
40◦C Initial
Temp.:
40◦C Column
Tempera-
ture:
40◦C
Hold Time 2.0min Hold Time 2.0min Injection Volume
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Rate 10.0
◦C/min
Rate 6.5 ◦C/min Leachable-
Study:
10 µL
End Temp. 320◦C End Temp. 300◦C Extractable-
Study:
0.5 µL
Hold Time: 10.00 min Hold Time: 3.00 min Mobile
Phase
A: Water
0.1% formic
acid; B:
Methanol
MSD
Transfer
Temp.:
300◦C MSD
Transfer
Temp.:
300◦C
Gradient
Time
Eluent
A
Eluent
B
0.0 min 80% 20%
0.5 min 80% 20%
8.0 min 3% 97%
16.0 min 3% 97%
16.1 min 80% 20%
20.0 min 80% 20%
MS Setting MS Setting MS Setting
MS Source: 230◦C MS Source: 230◦C MS
Source:
130◦C
MS Quad: 150◦C MS Quad: 150◦C Desolvation
Temp.:
550◦C
Desolvation
Gas Flow:
790 L/h
Scan range: 33 - 650 Scan range: 33 - 650 Scan
range:
100 - 1200
Threshold: 150 Threshold: 150 Capillary: 1.85 kV
Frequency: 2.4
scans/sec
Frequency: 2.4
scans/sec
Scan Time 1.0 sec
UPLC/QTOF-MS/MS Measurement of Non-Volatile Extractables
The extraction of non-volatile substances was achieved by using exaggerated conditions.
A solvent mix of water and ethanol with a ratio of 50:50 was applied in order to mimic a
water based protein drug product with surfactant content [5]. The tested SUSs were filled
with the solvent mix and sealed with glass stoppers. In order to prevent evaporation, the
extractable-studies for the tubes were performed in glass bottles containing ∼10 mL of
the solvent mixture. The filter with the non-polymer filter-housing was stored in a glass
container and fully submerged in the mixture. For the 200 L buffer-bag an identical scale-
down version of 3 L was chosen. The extractable-study was performed at approximately
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70◦C with exposure time that matched the maximally allowed contact-time of each SUS
in the filling-process (see Table 4.1). Note that the temperature was chosen just below
the boiling point of ethanol. Blank measurements were performed with aliquots of the
extracting solvent mixture in glass bottles and carried out under the same conditions.
Non-volatile compounds in the generated extract-solutions (0.5 µL sample) were identified
by reversed phase UPLC/QTOF-MS/MS analytic (equipped with C8 column) [34] at a
column temperature of 40◦C and flow rate of 350 µL/min. The ESI source was operated
with a desolvation temperature of 40◦C and flow rate of 350 µL/min. Further operating
parameters are listed in Table 4.3. Reference measurement was performed by injecting pre-
defined spiking substances on water ethanol basis into the UPLC-system, simulating a 0.1
ppm contamination. The compounds were identified at a scan range of 100-1200 m/z by
matching accurate monoisotopic masses to a proprietary, internal database (Roche GmbH)
and the handbook of Bolgar et al. [30].
Figure 4.3: Schematic representation of the EG/PDMS coated stir bar handling, includ-
ing the adsorption, the solvent-back-extraction (SBE) and the subsequent UPLC/QTOF-
MS/MS analysis of the sample.
Risk assessments of extractables
All identified extractables were evaluated regarding potential health and safety concerns
[15, 35]. The detected substances were classified in three categories with a generic threshold
of toxicological concern (TTC) according to the Cramer Class concept, which provides
guidelines for structural safety alerts [36, 37]. Categorization was performed based on
the data collected by Jenke et al. [38], and using the ELSIE-database [39] and Toxtree
Software (IDEAconsult Ltd) [40]. Beside aflatoxin-, N-nitroso- or azoxy-compounds that
were considered as high-potent mutagen, in vitro mutagenicity data was collected of ames
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salmonella typimurium and mouse lymphoma tests by literature [18].
4.2.3 Leachables
In order to evaluate the leaching behavior of SUSs in pharmaceutical drug manufacturing,
the leachable-study was carried out by taking multiple samples directly from the filling line
(sampling points marked in Figure 4.4). Two separate filling runs were examined (n=2) for
each drug product (drug product 1-3, Table 4.2). To demonstrate a worst-case scenario,
the maximum detected concentration of the two runs was listed and not the average.
To report leachables above a relevant toxic concentration an analytical evaluation thresh-
Cryo-
Mixing- Filtration-
Filter cartridges
Vials
Sampling
Sampling
Sampling
Sampling
Sampling
Buffer-bag
Thawing-set
Transfer-tube
Filling-
tube
Figure 4.4: Simplified schematic representation of the filling line that was considered in
this study. The different SUSs (pictured in color) and the representative sampling points
are highlighted. The filling process for all tested products started with thawing of the deep-
frozen drug substance in stainless steel vessels using a SUS, comprised of a thawing tube
and a connector (circulating pump: 1 L/min). Subsequently, the respective drug substance
was pooled by transferring the product from various cryo-vessels via silicon tubing to a
steel-based mixing vessel. For the drug products 1 and 2 buffer, prepared in a disposable
bag, was fed with varying volumes in using a peristaltic pump (300 rpm). Furthermore,
the product was filtered using a product specific number of single-use filters in polymer
cartridges. Finally, a silicon filling hose in combination with a peristaltic pump and shut-off
devices was used for injection of the product into vials.
old (AET) concept was applied. Therefore, the ICH M7 guideline defines an acceptable
4.2 Materials and Methods 69
daily intake (ADI) based on the worst-case assumption that all impurities may be of geno-
toxic concern. For the calculation the maximum lifetime dosing days, which are the number
of days are considered, which describes the number of days in a patient’s life for which the
drug is administered [17].
Sample Preparation
To analyze and quantify leachables with relevant concentrations in protein drug products
an enrichment and preparation step for GC and UPLC analytic was required. To en-
sure sufficient sensitivity, SBSE was performed using a stir-bar (Twister, Gerstel GmbH)
consisting of a 10mm long glass-encapsulated magnetic stir-bar. Stir-bars used with GC
were coated 24 µL of pure PDMS and those used with UPLC were coated with 32 µL of
the more polar EG(5%)-PDMS mix. As the SBSE technique is highly dependent on the
substances’ octanol/water coefficient (log KO/W ) [22], spiking-substances were chosen to
represent both, the lower limit of recovery and the optimal field of application.
(PDMS)-SBSE Coupled with TDS-GC-MS
For the GC-analysis, 1 mL drug sample was mixed with 4 mL WfI to ensure a total
cover of the stir-bar. The PDMS coated stir-bar was exposed to the solution for 1 h and
stirred at 800 rpm and 19◦C. Following the extraction step the stir-bar was rinsed with
WfI, dried by dabbing and placed in the autosampler. The operating parameters differ
from the extractable-method regarding the TDS end temperature of 300◦C and the CIS
initial temperature of -20◦C (listed in Table 4.3). Blank measurements were performed by
immersing a stir-bar in pure WfI, to verify the system contamination by estimating the
background noise. Reference measurements were done with stir-bars subjected to THF-
methacrylate and BHT-aldehyde spiked drug matrices. To make sure that the spiking
substances are not confounded by the same leachables in the drug product, drug product
blanks were performed as well. For this purpose, the spiking standards were dispersed in
ethanol by sonication at a concentration of 0.1 g/L and diluted with WfI to simulate the
drug product specific AET. To obtain semi-quantitative measurements, linearity solutions
were prepared from the same stock solution by diluting with WfI to 0.001, 0.005, 0.01, 0.05
and 0.1 mg/L. Linear regression analysis was performed, and the correlation coefficient
(r2) was estimated using Masshunter Quantitative Analysis (Gerstel GmbH). The limits
of detection (LOD) and quantification (LOQ) were calculated as the minimal amount of
analytes that result in a signal-to-noise-ratio (SNR) of 3 or 10, respectively. Here, the SNR
is defined as the peak height of the spiking substance and the baseline noise adjacent to
the peak including a range of 0.05 min before and after the peak. The noise value for each
noise range is computed as the standard deviation of the baseline over the mean of the
selected noise region. The SNRs were determined at four concentrations, and the results
were linearly interpolated. Confidence intervals were calculated using the fit residuals.
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(EG/PDMS)-SBSE Coupled with SBE-UPLC/QTOF-MS/MS
The EG/PDMS coated stir-bar was immersed in 5 mL drug sample and stir-bar handling
was performed as described above. For the SBE-step, the stir-bar was transferred in 1 mL
pure acetonitrile and stirred for another 30 min, followed by a sonication-step of 20 min. Of
the generated solution 10 µL were directly injected into the UPLC system (same operating
parameters listed as the extractable-method, in Table 4.3). For the blank measurement the
SBSE procedure was conducted in pure WfI. The reference measurement was performed by
dissolving the polar spiking substances in ethyl acetate under sonication at a concentration
of 1 g/L. Again, the specific AET was simulated and linearity solutions were prepared by
diluting the stock solution with WfI corresponding to concentrations of 0.01, 0.025, 0.05,
0.075, 0.1 and 0.2 mg/L, respectively. For each of the spiking substances linearity, LOD
and LOQ were analyzed as described above.
Safety Concern Thresholds for Mutagenic Leachables
Leachables with concentrations above the estimated AET were characterized using the
NIST library and an internal library (Roche GmbH), their exact concentration determined
and reported for potential toxicological assessments. To demonstrate leachable-profiles
over the filling process and to assign leachables to each SUS by matching to the generated
extractable-footprints, even leachables below the AET were identified and semi-quantified
for this study.
4.2.4 Absorbance and Filtering of Leachables
In order to retrace leached substances inside the filling line, a scale-down version of the
filling line was designed. The endless circle filling line comprised an identical scale-down
model of the applied filter, the transfer and the filling tubing. A peristaltic pump was
used to circulate the test-solution in the system for 3 h at a speed of 3.5 L/h. The system
was run with 0.1 ppm diethyl phthalate spiked WfI to observe a potential absorption of
the plasticizer by SUSs in the system. The concentration of the spiking substance in the
solution was analyzed after the test-run with the use of the SBSE method in combination
with TD-GC-MS, as described above.
4.2.5 Impact of the Active Ingredient on the Leachable Spectrum
To uncover potential interaction between the active ingredient and the leachable release,
samples were taken during the drug product filling, as depicted in Figure 4.4, for fillings
of drug product product 4 and placebo (Table 4.2). Leachable profiles were compared
between the runs regarding leachable types and concentrations. This enabled to reveal
possible extraction from the SUS driven by the protein during the filling process of the drug
product. Furthermore, the identification of some leachables may be hampered for samples
from the actual filling process as interaction with the active protein prevents detection
with GC-and LC-MS. The impact of the protein on leachable extraction was analyzed with
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SBSE and subsequent TDS-GC-MS analysis, as described above. The compared runs were
performed with identical filling lines, except for two modifications. For the placebo-run,
the buffer was prepared in a disposable bag instead of being dispensed from a cryovessel.
Hence, no thawing set and no transfer tubing was applied for processing of the placebo.
4.2.6 Impact of the Drug Product pH
The impact of the drug product’s pH-value on the leaching behavior during the filling
process was evaluated. Four drug products with different pH-values were tested (pH ∼3.5
to ∼10.0, Table 4.2). The samples were drawn from two spots, the cryovessel and the
filled vial at the end of the filling process. All other SUSs, except the buffer-bag were
applied for the filling of the the four drug products (see Table 4.2). Filters with different
membrane materials had to be used for different products, due to the major variation in
pH-values. The extractable-footprints of all filters can be found in chapter 3. The samples
were analyzed by SBSE and subsequent TDS-GC-MS analysis, as described above.
4.3 Results
4.3.1 Extractable-Profiles
Extractable profiles for all SUS as generated with thermal and static extraction are listed
in the Tables 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 4.10, 4.11, 4.12 and 4.13,. After identification, the
detected extractables were compared to the expected foot print of each material as taken
from literature [41] (Table 4.1).
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Silicone Tubes
GC-MS analysis reveals comparable chromatographic fingerprints with respect to the peak
number and magnitude for all three tested silicone-tubes (see Figure 4.5, C-D-E). The
chromatograms are dominated by large peaks attributable to a homologous series of polydi-
methyl-siloxanes (Si), as commonly observed in thermal extraction from silicone materials
[42]. The largest peaks are associated with cyclic oligomers with the general structural
formula of [(CH3)2SiO]n. A number of minor peaks were identified as various phthalate
based plasticizers, which are used to promote flexibility of the polymer structure of the
tube. Residual substances detected in the chromatogram include, different kinds of naph-
thalenes, that are in turn used for the production of phthalates, 2-hexyl-1-decanol and
2-ethyl-1-hexanol, metabolites of the production in particular for diester bis(2-ethylhexyl)
phthalate (DEHP) and 4-(1,1-dimethylethyl)-cyclohexanol, a catalyst and precursor of
DEHP. Although many phthalates and intermediates of the production of DEHP were de-
tected as extractables, DEHP itself was not observed. Furthermore, beside many intermedi-
ates and lubricants 1-(2-butoxyethoxy)-ethanol and 2-(2-ethoxyethoxy)-ethanol, which are
commonly used as solvents and preservatives in siloxane production were found in mod-
erate amounts in the extractable profile. Two substances were observed that are known
to be carcinogen, the antioxidant 2,4-di-tert-butyl-6-nitro-phenol and traces of the solvent
benzaldehyde [43]. The Si thawing tubing demonstrated a large number of siloxanes by
UPLC with static extraction, which can likely be linked to its softer material properties
(peaks from 7.5 to 9.5 min; Figure 4.6). The transfer and filling tube contained triethyl
phosphate, tributyl phosphate and a high concentration of the anti-infective agent 1,2-
diacetate-glycerol and triacetin (retention time of 2.32 min, Figure 4.6).
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In addition to the above listed substances tetramethylbutyl phenol and trimethylol-
propane trimethacrylate were extracted from the polysulfone (PS) connector of the thawing
system. Two benzenes, 1,1’-(1-methylethylidene)bis[4-methoxy]-benzene and 1-methoxy-
4-[(E)-2-phenylethenyl]benzene were found and are commonly observed as building blocks
of the PS material [41]. UPLC analysis identified an additional benzene the large molecule
bisphenol p. Further, sulfurous molecules were revealed as potential leachables of the PS.
Bag and Filter
Direct material TD analysis of the buffer-bag and filter indicated the presence of neither
carcinogenic nor mutagenic substances. Figure 4.5 (F) depicts the bag profile marked with
a homologous series of polydimethylsiloxanes, which can be attributed to the bag tubing.
Moreover, broad peaks of alkanes, extracted from the polypropylene (PP) material are ob-
served. In contrast, the filter cartridge chromatogram demonstrated recurring peak-blocks
that are associated with an unknown substance (m/z: 79) and straight and non-straight
chain alkanes. The major peak at 21.66 min can be identified as the alkane heptacosane.
A further major peak is observed at 15.498 min, which is the antioxidant break-down 2,4-
bis(1,1-dimethylethyl)-phenol. The filter resulted in the lowest amount of extractables of
all tested SUSs. Only diethyl phthalate and two adipates, di-(2E)-2-buten-1-yl adipate
and di(2-ethylhexyl) adipate (DEHA) could be identified as plasticizers. Additional peaks
were found to correspond to antioxidants, including butylated hydroxytoluene (BHT), a
molecule that is controversially discussed in literature regarding its toxicity [44, 45].
The polyethylene (PE) material of the buffer-bag revealed the oligomers 3,4’,5,6’-
tetrakis(2-methyl-2-propanyl)-2,3’-biphenyldiol and tetraethyl 1,4-diphenyl-1,1,4,4-butane-
tetracarboxylate, as detected with UPLC/QTOF-MS/MS. Furthermore, fragments includ-
ing o-hydroxyacetophenone and 2,4-di-tert-butylphenol could be thermally extracted at
150◦C and were detected with GC-MS. Di-tert-dodecyl disulfide, butyl ester 6-tetradecane-
sulfonic acid and octadecyl pentyl ester sulfurous acid were found as extractables of the
thermoplastic elastomer bag port. These sulfurous chemicals are commonly used as lubri-
cants and lubricant additives [39]. In comparison to the other SUSs, higher concentrations
of fatty acids were found in the bag. These additives were likely employed to promote flexi-
bility and to function as slip agents and lubricants for the diverse bag-materials. These are
also stated reported to be commonly encountered extractables of polyethylene in literature
[41]. The large peak with a retention of 9.28 min (in both ionization modes, Figure 4.6)
could be attributed to a phosphor based additive with the chemical formula C39H59N2O7P .
4.3.2 Leachables
It was previously demonstrated (chapter 2) that SBSE provides sufficient sensitivity for
semi-quantitative assessment [21]. Applicability of the proposed SBSE analytical set-up for
leachable detection and quantification in drug products was verified by studying the range
of measurement linearity (Table 4.14). Calibration plots depict high linearity (r2 > 0.990)
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Figure 4.6: Static extraction with an ethanol water mix from the SUSs. Depicted are the
UPLC/QTOF-MS/MS chromatograms in positive (color blue) and negative (color green)
ionization mode: A) Blank: Aliquot of the ethanol/water mix; B) Reference measurement:
Solvent mix spiked with 0.1 ppm of UVA P (pos. RT: 6.69 min), Tinuvin 328 (pos. RT:
9.08 min), Uvitex OB (pos. RT: 8.89 min) and Irganox 1010 (neg. RT: 9.88 min); C)
Thawing system: Extraction time (ET) 17 h. D) Transfer system: ET 24 h. E) Filling
system: ET 72 h. F) Bag system: ET 24 h. G) Filter system: ET 8 h.
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up to the LOQ of 0.1 and 2.0 mg/L for TD-GC-MS and SBE-UPLC/QTOF-MS/MS,
respectively see Table 4.14). The LOD for the SBSE method in combination with the
TD-GC-MS was assessed as 2.2 - 0.6 µg/L and the LOQ as 2.1 and 7.3 µg/L for the two
spiking substances, respectively. In combination with the SBE-UPLC/QTOF-MS/MS ana-
lytic, LODs between 0.003-0.025 mg/L and LOQs between 0.011-0.083 mg/L were achieved
see Table 4.14). The ADI for all drug products examined in this study was between 20 and
120 µg/day per impurity. Dividing the regulated threshold by the drug specific dose results
in the AET, which ranged from 0.2 to 6.0 ppm for single mutagenic leachables (multiple
impurities 0.6 – 6.0 ppm) in the examined drug products (see Table 4.2).
Table 4.14: Correlation coefficient for the tested linear range of each spiking substance
and the quantitative limits of SBSE observed for PDMS and EG/PDMS coated stir-bars
in combination with TD- GC-MS and SBE-UPLC/QTOF-MS/MS analytic.
Analyte Spiking sub-
stances
Linear
range
[ppm]
Correlation
coefficient
(r2) (Ori-
gin: Force)
Precision
method re-
peatability
[%] RSD
(n=4)
LOD
[ppb]
LOQ
[ppb]
PDMS stir-bar;
TDS-GC-MS
THF-
methacrylate
0.007-0.1 0.9989 7.7 2.2 7.3
BHT-
aldehyde
0.002-0.1 0.9954 7.3 0.6 2.1
EG/PDMS
stir-bar;
SBE-UPLC/
QTOF-MS/MS
UVA P 0.011-2.0 0.9934 6.5 3.3 10.9
Tinuvin 328 0.028-2.0 0.9952 7.0 8.5 28.1
Uvitex OB 0.025-2.0 0.9919 8.0 7.7 25.2
Irgafos 168 0.074-2.0 0.9920 8.9 22.4 74.0
Irganox 1330 0.08-2.0 0.9915 11.9 24.1 79.8
Irganox 1010 0.083-2.0 0.9902 12.6 25.2 83.3
Samples were directly taken from the filling line during processing at five different
spots. A full account of all leachables, as detected with SBSE, is provided in Table 4.15
and 4.16 ordered by the respective sampling spots. The results are in agreement with the
extractable study, as leachables form a subset of previously identified extractables. The
first run of drug product 1, which is characterized by a high protein concentration (Table
4.2), yields only four leachables with semi-quantified concentrations above the LOQ. The
concentrations fall well below the AET of 6 ppm. One of the detected leachables was
triacetin, a non-genotoxic, commonly used plasticizer, which was observed only at the first
sampling point of the filling line with a sub-critical concentration of 33 ppb (RT: 17.22
min; Figure 4.7). Furthermore, dibutyl phthalate (see zoom Figure 4.7), a well-known
plasticizer, originated from the buffer bag and remained detectable throughout the filling
process, finally ending up in the vial with a negligible concentration below the LOQ. In
4.3 Results 101
both sampling-runs of drug product 1 acetophenone was observed, a substance that re-
sults from antioxidant-breakdown. Further, two amides were detected as leachables with
low concentration. Lastly, an unknown siloxane was detected with UPLC [m/z: 792.6278;
813.557] (RT: 9.87 min; Figure 4.7).
In the second run of drug product 1, a higher number of unknown substances was ob-
served with UPLC analytic. One of the unknown substances [m/z: 362.099; 533.1563],
with a concentration of 417 ppb, was present in the sample taken from the buffer-bag.
However, this is still well below the drug product’s individual AET. This substance could
not be identified with respect to the extractable-footprint of the associated SUSs. Thus,
it is considered to be a buffer-impurity. The substance consisted throughout the filling
process and was detected with a concentration of 274 ppb in the vial.
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Both runs of the second drug product, which has a high content of polysorbate 80 and
a significantly lower AET, show that the majority of leachables was already found at the
first sampling point in the filling line, i.e. in the cryo-vessel. Most of the detected leach-
ables were substances that were also observed as extractables of the thawing tube with the
PS-connector. Only two substances remained detectable throughout the filling process and
ended up in the vial: 2-(2-butoxyethoxy)-ethanol acetate and the antioxidant 7,9-di-tert-
butyl-1-oxaspiro(4,5)-deca-6,9-diene-2,8-dione. These two substances were consistently de-
tected with both analytic techniques. The ethanol 2-(2-butoxyethoxy)-acetate was picked
up by TD-GC-MS in the cryo-vessel and in the vial, and as 2-(2-butoxyethoxy)-ethanol
it was detected with SBE-UPLC/QTOF-MS/MS in the mixing and filtration vessel. The
concentration of this nontoxic leachable, which can be traced back as extractable of the
thawing- and transfer tubing, decreased over the filling process from 44 to 10 ppb. At no
sampling spot, the concentration of the leachable exceeded the drug based AET of 200 ppb.
The other persistent substance, 7,9-di-tert-butyl-1-oxaspiro(4,5)-deca-6,9-diene-2,8-dione,
was also confirmed with both analytics but with even lower concentrations. The leachables
with the highest identified concentrations at any point of the filling line were phthalates
in the cryo-vessel of the second run (cumulative of 128 ppb). However, the substances did
not persist at subsequent sampling points.
For the last tested drug product, no SUS bag was applied and hence, no dilution by
buffer inflow was necessary. Again, a consistent decrease of leachables was observed over the
course of the filling process. Over both runs a total of twelve leachables whose concentra-
tions exceeded the corresponding LOQ were detected. For this drug product three sulfurous
leachables were observed in both runs, which were not present for the other drug products.
These leachables included 4-undecylbenzenesulfonic acid, methyl tetrapropylenebenzene-
sulphonate and an unknown substance with the chemical formula C15H33N2PS. Those
sulfurous leachables occurred with comparably high concentrations (up to 495 ppb at the
beginning of the filling process) but still fell below the AET of 500 ppb. Furthermore,
a sharp decrease of the concentration over the course of the filling process was observed.
Besides the sulfurous substances, all other detected leachables in the cryo-vessel could not
be matched to extractables from the thawing-system. Remaining leachables that occurred
during the process were diverse phthalates, with concentrations mostly below the LOD.
The total concentration of all leachables over all tested drug products listed in Table
4.17 depicts a remarkable decrease over the filling process to about 1/6 of the concentration
at the end compared to the start of the filling process (Figure 4.1).
4.3.3 Absorbance and Filtering of Leachables
To confirm an uptake of leachables by SUSs, a scale-down version of the filling line was
run with a commonly occurring leachable. Comparing the concentration of the plasticizer
diethyl phthalate in the solution before and after processing in the test version of the
filling line reveals a decrease in quantity. After a contact time of 3 h to the SUSs the
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Figure 4.7: (Figure caption continued on page 116.)
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Time [min]
C
o
u
n
ts
 [
%
] A)
21
1.58e6
C)
16
1.70e6
D) 9.97
15
1.61e6
E) 9.97
13
1.69e6
F) 9.97
12
1.79e6
G)
2.24e6
B)
19
1.29e6
9.88
Figure 4.7: Leachable-study of drug product 1. Chromatograms using PDMS stir-bar
in combination with TD-GC-MS are depicted: A) Blank: Stir-bar immersed in pure
WfI. Peaks correspond to stir-bar bleeding; B) Reference measurement: Drug product
spiked with 0.2 ppm (lowest AET-value 0.2 ppm/drug product 1 AET 6 ppm) of THF-
methacrylate (RT: 6.69 min) and BHT-aldehyde (RT: 9.08 min); Additional peaks corre-
spond to surfactant of the drug product. C) Drug sample: Cryo-vessel sampling point.
Detected leachables above LOQ are indicated by RT-marks. D) Drug sample: Buffer-bag.
E) Drug sample: Mixing-vessel. F) Drug sample: Filtration-vessel. G) Drug sample: Vial.
H) NIST m/z spectrum of the leachable dibutyl phthalate at 27.991 min. J) Peak-overlay
of dibutyl phthalate in the different drug samples.
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Table 4.17: The in total concentration of all detected leachables for all three drug products
over both sampling runs at each sampling point.
PDMS stir-bar TD-GC-
MS; EG/PDMS stir-bar
SBE-UPLC/QTOF-
MS/MS Drug product 1-3,
run 1 -2
Cryo-
vessel –
Sampling
(1)
Buffer Bag
- Sampling
(2)
Mixing-
vessel –
Sampling
(3)
Filtration-
vessel –
Sampling
(4)
Vial –
Sam-
pling
(5)
Summation of the con-
centration of all detected
leachables over the three
drug products [ppm]
2.020 0.442 (only
for drug
product 1
& 2)
0.798 0.576 0.342
concentration of the plasticizer was halved from 0.1 ppm to 0.053 ppm.
4.3.4 Impact of the Active Ingredient on the Leachable Spectrum
A full account of all leachables, as detected with SBSE combined with TD-GC-MS analysis,
is provided along with the sample points in Table 4.18. Samples were taken directly from
the filling line during processing of the drug product 4 and the corresponding placebo. The
leachable profiles detected in the two runs were compared to assess the impact of protein
in leachable-studies. However, some of the SUSs varied for the filling-process of the drug
product compared to the placebo. The following three leachables were found in both runs:
An unknown substance at the last sampling point, butylated hydroxytoluene (BHT), a
well known antioxidant, and phthalic acid, butyl hept-4-yl ester, a plastizicer breakdown
product. The last two substances were found with different concentrations in the filling
process. For these two substances, a decrease over the filling line was detected. One
substance was found in the drug product run only. This substance 2-(2-butoxyethoxy)-
ethanol acetate leached out of the transfer tube during the contact to the drug product.
All remaining leachables were present only at very low concentrations well below the LOQ.
4.3.5 Impact of the Drug Product pH
Four drug products with pH-values ranging from acidic to basic were examined. All leach-
ables were detected with SBSE, combined with TD-GC-MS analysis, and provided in
Table 4.19. A clear trend of increased leachable contamination with increasing pH-value
of the drug product was observed. For the drug product with the highest pH-value (pH
10 - product 8), the highest cumulative leachable concentration (0.307 ppm) was detected.
However, this was still well below the individual AET for multiple impurities, which was
at 2.25 ppm. In addition, substances with non-polar surface area were found in higher
concentrations in the basic drug product compared to the ic and neutral drug products.
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4.4 Discussion
The present study evaluated the risk of leachables migrating from SUSs, applied throughout
the pharmaceutical filling process, into the final drug product in order to assess potential
patient hazards. Samples were drawn at multiple points from a real-life production line and
were analyzed with TD-GC-MS and UPLC/QTOF-MS/MS to detect relevant impurities.
Additionally, extractable-studies were conducted with thermal extraction of the polymers
at high temperatures and static extraction, enabling the characterization of extractable
foot prints of each SUS. Those footprints provide an overview of the extractables, which
can be expected as typical substances of the different polymer-materials (listed in Table 1)
or which are observed as additives subject to manufacturing variability. Our results indi-
cate that all relevant impurities were well below the safety threshold, and often decreased
in quantity throughout the manufacturing line. Thus, this study concludes, that leachables
do not pose a major health hazard in pharmaceutical processing.
Thermal extraction was chosen for the extractable study due to its ease-of-use and
the fast turnaround of this method. Compounds with comparably high mobility within
the polymer matrix are most readily extracted using thermal extraction [32]. Hence, this
method is well suited to provide an overview of the most relevant leachable-candidates.
However, to obtain a more comprehensive picture of the extractable footprint, a static ex-
traction procedure in combination with UPLC/QTOF-MS/MS analytic was performed in
order to assess non-volatile high molecular weight substances. None of the substances that
were only extracted under harsh conditions using a solvent-mix in the static extraction has
been observed in the drug product as leachables. Thus, substances with lower mobility
rates are unlikely to leach out of the SUS material during the filling process under normal
process-conditions with a comparably short contact time. These results indicate that ther-
mal extraction seems to be well suited for detection of leachable candidates in real world
processing. Static extraction seems to be only necessary if a complete extractable-footprint
is required. In addition, the levels of the leachables during the filling process detected with
the GC-MS analytics were higher than for the UPLC/QTOF-MS/MS analytics.
For leachable-studies the applicability of the SBSE method in combination with TD-
GC-MS and SBE-UPLC/QTOF-MS/MS was evaluated. The limits of detection in the
tested drug matrices were well below the guideline regulated AET of the tested drug prod-
ucts [17]. SBSE analysis allowed fast and easy quantitative measurements even in presence
of the drug matrix. However, our results indicate that no quantification of siloxane frag-
ments in the drug product can be performed, as bleeding of the PDMS stir-bar coating is
interfering. Despite this limitation the presented sample-preparation technique seems to be
readily applicable and effective in detection of residual leachables with GC and UPLC ana-
lytics in drug products, with the potential for quantitative or semi-quantitative assessment.
SBSE has previously been used for detection of leachables and extractables in pharma-
ceutical processing [46]. B. Athensta¨dt developed GC-MS methods in combination with
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SBSE for the identification and quantification of leachables from plastic packaging in dial-
ysis solutions. In this study build upon this literature, by exploiting the high sensitivity of
SBSE to analyze samples from a real-world filling line equipped with a variety of polymers
for different drug products. Impurity studies in pharmaceutical drug products were largely
restricted to extractable-data for polymer materials in previous literature [11, 47, 48]. In
this study we present the analysis of three drug products in a real-world filling line. Be-
sides the presented data no other pharmaceutical products were studied, and none were
excluded from analysis. The results coherently demonstrate low exposure to leachables, far
less than the relevant safety threshold.The majority of leachables was detected at the first
sampling point, but only half of them were also observed as extractables of the thawing
tubing with the connector. It is plausible that those substances have already been present
in the delivered bulk drug substance solution and only partially originated in the thaw-
ing set. Other leachables that have not been identified as extractables were observed in
the drug-product samples from the buffer-bag. This provides further evidence that most
leachable exposure happened before entering the filling process, due to increased stress
including longer contact times, and that impurities are contained in the buffer components
that are fed into the drug.
Drug product 3 compared to the other tested drug products had the highest leachable
concentration. However, among all leachables only sulfides were depending on the actually
filled product. These leachables (C24H50S2; C18H38O3S; C23H48O3S) were identified in the
cryo-vessel of both runs of drug product 3, but for no other product. Those can be traced
to the PS material of the connector. Although these substances were not identified by the
extractable-studies, larger sulfurous substances like C22H14N2S2 and C26H24N2O5S were
extracted by static extraction. Therefore, these leachables are likely to be breakdown-
fragments of the determined extractables of the connector, resulting from different interac-
tions of the drug product formulation with the material compared which do not occur with
the solvent mix during the extraction-study. However, again it cannot be fully excluded
that these leachables were already in the delivered bulk and originated from a SUS of
the preceding manufacturing. Besides this group, no other direct influence of the product
composition on the nature of the detected leachables was observed.
The impact of proteins on the leachable spectrum was tested by comparing a drug
product filling with a placebo filling. Identical leachables were observed in both runs, in-
dependent of the filled solution, although with different concentrations. These differences
in concentration were mostly due to minor, random variations between fillings (compare
subsection 4.3.2), and were not a result of protein interaction. Only one leachable that was
not detected in the placebo-run, was observed in the drug product filling with a concen-
tration higher than the LOQ. Based on the ectractable-footprints, this leachable can be
traced to a single-use transfer tube, which was not applied for the placebo filling. Hence,
it is questionable whether the leachable results from the protein impact. Furthermore,
the impact of the drug product’s pH was investigated. Although, not exactly the same
SUSs were used for the different drug products, a pH effect on the leachables spectrum was
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demonstrated.
The use of platinum-cured silicone tubing is expected to result in low extractable/leachable
levels [49]. However, in pharmaceutical processes SI tubes are most commonly used. Our
study revealed that larger amounts of extractables, including some with mutagenic concern
were obtained from these tubing compared with other SUSs. The SUS with the highest ex-
posure was the thawing tube with connector. Only few leachable substances exceeding the
LOQ were found following the filters despite their high drug volume contact. Although,
the bag had the highest contact surface, this SUS was irrelevant for the overall leach-
able outcome in the product. All in all, no significant leachable enrichment was observed
throughout the filling process by any particular SUS.
Our results show that in the commercial manufacturing pipeline leachables were only
found in extremely low concentrations, mostly below the LOQ. Despite the use of numerous
SUSs in the process, the maximum detected leachable concentration did not once exceed the
reporting threshold given by the ICH. The concentrations were particularly low in the final
sampling point, i.e. in the filled vials. Leachables, which were observed to migrate from the
SUSs into the drug products, were mostly plasticizers in form of phthalates and antioxidant
breakdowns. All substances were categorized as non-mutagenic and non-carcinogenic. Nei-
ther benzaldehyde nor 2,4-di-t-butyl-6-nitro-phenol or o-hydroxybiphenyl, the only iden-
tified genotoxic substances in the extractable-study, were detected as leachables in the
tested drug products. This highlights the importance of leachable studies, besides ex-
tractable analysis, to allow for accurate classification and to avoid misleading worst-case
conclusions.
Many substances, which were present in the beginning of the filling line, could not be
detected in the vial anymore, indicating a major reduction in concentration of leachables
during the process in our study. This is most likely caused by API-pooling and buffer-
dilution. However, even for drug product 3, which did not employ dilution by buffer, an
extreme reduction over the filling process was observed. The absorbance of leachables by
filters and tubes is a likely explanation for the reduction of the concentration, as they
provide high surface areas for interaction with leachables. We were able to confirm this
uptake of leachables by SUSs for a plasticizer in a scale-down filling line experiment. This
result is in good agreement with a previous work by Hauk et al. [50], which describes filters
used for sterile filtration, acting as scavengers of leachables in an experimental set-up.
4.5 Conclusion
With this study we were able to identify and quantify accumulation of leachables in real-
world commercial scale industrial drug-filling lines for protein drug products in order to
shed light on the actual patient exposure, beyond the classical extractable-studies. We
have demonstrated that leachables have only a marginal contribution to parenteral solu-
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tion contamination and that SUSs in the filling line even exert scavenging behavior for
leachables, resulting in a decrease in concentration within the drug processing, instead of
contaminating the product. But still, each drug product, especially its pH-value, and each
SUS can influence the leachable-outcome of a filling-processing.
BIBLIOGRAPHY 127
Bibliography
[1] N. Scherer, K. Marcsekova´, T. Posset, and G. Winter. New Studies on Leachables
in commercial scale Protein Drug Filling Lines using Stir Bar Sorptive Extraction
coupled with TD-GC-MS and UPLC/QTOF-MS/MS analytics. International Journal
of Pharmaceutics, 30(555):404–419, 2018.
[2] A. A. Shukla and U. Gottschalk. Single-use disposable technologies for biopharma-
ceutical manufacturing. Trends in Biotechnol., 31(3):147–154, 2013.
[3] U. Gottschalk. Disposables in Downstream Processing. Adv. Biochem. Eng. Biotech-
nol., 115:171–183, 2009.
[4] E. S. Langer and R. A. Rader. Single-use technologies in biopharmaceutical manu-
facturing: A 10-year review of trends and the future. Eng. Life Sci., 14(3):238–243,
2014.
[5] U.S. Pharmacopeia. Draft: Polymeric Components and Systems Used to Manufacture
Pharmaceutical and Biopharmaceutical Drug Products. USP 665, 2016.
[6] U.S. Pharmacopeia. Draft: Characterization of Polymeric Components and Systems
Used to Manufacture Pharmaceutical and Biopharmaceutical Drug Products. USP
1665, 2016.
[7] Food and Drug Administration. Section 211.65 - Equipment construction. FDA US
21, 2010.
[8] Steven A. Zdravkovic, Cindy T. Duong, Ashley A. Hellenbrand, Steven R. Duff, and
Alyssa L. Dreger. Establishment of a reference standard database for use in the qual-
itative and semi-quantitative analysis of pharmaceutical contact materials within an
extractables survey by GC–MS. Journal of Pharmaceutical and Biomedical Analysis,
151:49–60, 2018.
[9] A. Wakankar, Y. Wang, E. Canova-Davis, S. Ma, D. Schmalzing, J. Grieco, T. Milby,
T. Reynolds, K. Mazzarella, Ed Hoff, S. Gomez, and S. Martin-Moe. On develop-
ing a process for conducting extractable-leachable assessment of components used for
storage of biopharmaceuticals. J. Pharm. Sci., 99(5):2209–2218, 2010.
[10] D. Jenke. Compatibility of pharmaceutical products and contact materials: safety
considerations associated with extractables and leachables. John Wiley & Sons, 2009.
[11] C. Pan, F. Harmon, K. Toscano, F. Liu, and R. Vivilecchia. Strategy for identification
of leachables in packaged pharmaceutical liquid formulations. Journal of Pharmaceu-
tical and Biomedical Analysis, 46(3):520–527, 2008.
[12] D. Jenke. Linking Extractables and Leachables in Container/Closure Applications. J.
Pharm. Sci. Technol., 59(4):265–281, 2005.
128 BIBLIOGRAPHY
[13] D. L. Norwood, D. Paskiet, M. Ruberto, T. Feinberg, A. Schroeder, Guirag
Poochikian, Qingxi Wang, Tian Jing Deng, Fran DeGrazio, Melinda K. Munos, and
Lee M. Nagao. Best Practices for Extractables and Leachables in Orally Inhaled
and Nasal Drug Products: An Overview of the PQRI Recommendations. Pharma.
Research, 25(4):727–739, 2008.
[14] K. Li, G. Rogers, Y. Nashed-Samuel, H. Lee, A. Mire-Sluis, B. Cherney, R. Forster,
P. Yeh, and I. Markovic. Creating a Holistic Extractables and Leachables (E&L)
Program for Biotechnology Products. PDA Journal of Pharmaceutical Science and
Technology, 69(5):590–619, 2015.
[15] T. H. Broschard, S. Glowienke, U. S. Bruen, L. M. Nagao, A. Teasdale, Cheryl L.M.
Stults, Kim L. Li, Laurie A. Iciek, Greg Erexson, Elizabeth A. Martin, and Douglas J.
Ball. Assessing safety of extractables from materials and leachables in pharmaceuti-
cals and biologics – Current challenges and approaches. Regulatory Toxicology and
Pharmacology, 81:201–211, 2016.
[16] D. Jenke. Evaluation of the chemical compatibility of plastic contact materials and
pharmaceutical products; safety considerations related to extractables and leachables.
J. Pharm. Sci., 96(10):2566–2581, 2007.
[17] International Conference of Harmonisation (ICH). M7 Assessment and Control of
DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Car-
cinogenic Risk. Guidance for Industry, 2015.
[18] A. Amberg, L. Beilke, J. Bercu, D. Bower, A. Brigo, K. Cross, L. Custer, K. Dobo,
E. Dowdy, K. Ford, S. Glowienke, J. Van Gompel, J. Harvey, C. Hasselgren,
M. Honma, R. Jolly, R. Kemper, M. Kenyon, N. Kruhlak, P. Leavitt, S. Miller,
W. Muster, J. Nicolette, A. Plaper, M. Powley, D. Quigley, V. Reddy, H. Spirkl,
L. Stavitskaya, A. Teasdale, S. Weiner, D. Welch, A. White, J. Wichard, and G. My-
att. Principles and procedures for implementation of ICH M7 recommended (Q)SAR
analyses. Regulat. Toxicol. Pharmacol., 77:13–24, 2016.
[19] B. Xiao, S. K. Gozo, and L. Herz. Development and validation of HPLC methods for
the determination of potential extractables from elastomeric stoppers in the presence
of a complex surfactant vehicle used in the preparation of parenteral drug products.
Journal of Pharmaceutical and Biomedical Analysis, 43(2):558–565, 2007.
[20] D. L. Norwood, D. Jenke, C. Manolescu, S. Pennino, and N. Grinberg. HPLC and
LC/MS Analysis of Pharmaceutical Container Closure System Leachables and Ex-
tractables. J. Liq. Chromatogr. Related Technol., 32(11-12):1768–1827, 2009.
[21] N. Scherer, K. Marcsekova´, T. Posset, and G. Winter. Evaluation of stir-bar sorptive
extraction coupled with thermal desorption GC–MS for the detection of leachables
from polymer single use systems to drugs. Journal of Pharmaceutical and Biomedical
Analysis, 152:66–73, 2018.
BIBLIOGRAPHY 129
[22] B. Armstrong, A. Senyurt, V. Narayan, X. Wang, L. Alquier, and G. Vas. Stir bar
sorptive extraction combined with GC-MS/MS for determination of low level leachable
components from implantable medical devices. J. Pharma. Biomed. Analysis, 74:162–
170, 2013.
[23] F. Nogueira. Novel sorption-based methodologies for static microextraction analysis:
A review on SBSE and related techniques. Analytica Chimica Acta, 757:1–10, 2012.
[24] A. Prieto, O. Basauri, R. Rodil, A. Usobiaga, L.A. Fernandez, N. Etxebarria, and
O. Zuloaga. Stir-bar sorptive extraction: A view on method optimisation, novel appli-
cations, limitations and potential solutions. J. Chromatogr. A, 1217(16):2642–2666,
2010.
[25] E. Baltussen, C. Cramers, and P. Sandra. Sorptive sample preparation - a review.
Analyt. Bioanalyt. Chem., 373(1-2):3–22, 2002.
[26] D. Jenke, T. Egert, A. Hendricker, J. Castner, T. Feinberg, C. Houston, D. G. Hunt,
M. Lynch, K. Nicholas, D. L. Norwood, D. Paskiet, M. Ruberto, E. J. Smith, F. Hol-
comb, and I. Markovic. Simulated Leaching (Migration) Study for a Model Container-
Closure System Applicable to Parenteral and Ophthalmic Drug Products. PDA Jour-
nal of Pharmaceutical Science and Technology, 71(2):68–87, 2017.
[27] S Go¨ro¨g. Identification and determination of impurities in drugs. Elsevier, Amster-
dam; New York, 2000. OCLC: 162130921.
[28] D. Jenke. Guidelines for the Design, Implementation, and Interpretation of Valida-
tions for Chromatographic Methods used to Quantitate Leachables/Extractables in
Pharmaceutical Solutions. J. Liq. Chromatogr. Related Technol., 27(20):3141–3176,
2004.
[29] N. Magarian, K. Lee, K. Nagpal, K. Skidmore, and E. Mahajan. Clearance of ex-
tractables and leachables from single-use technologies via ultrafiltration/diafiltration
operations. Biotechnol. Prog., 32(3):718–724, 2016.
[30] M. Bolgar, J. Hubball, J. Groeger, and S. Meronek. Handbook for the chemical analysis
of plastic and polymer additives. CRC Press, Taylor & Francis Group, Boca Raton,
second edition edition, 2016.
[31] C. Zweiben and A. J. Shaw. Use of thermal desorption GC-MS to characterize pack-
aging materials for potential extractables. J. Pharm. Sci. Technol., 63(4):353–359,
2009.
[32] A. Hoffmann and T. Albinus. Extractables and Leachables Analysis of IV Bag Sys-
tems. Agilent Technologies, 2015.
[33] V. Shen. Standard Reference Simulation Website, NIST Standard Reference Database
173. National Institute of Standards and Technology, 2006.
130 BIBLIOGRAPHY
[34] Y. Zhang, S. Sun, X. Xing, Z. Du, Q. Guo, and W. Yu. Detection and Identification
of Leachables in Vaccine from Plastic Packaging Materials Using UPLC-QTOF MS
with Self-Built Polymer Additives Library. Analytical Chemistry, 88(13):6749–6757,
2016.
[35] L. Mu¨ller, R. J. Mauthe, C. M. Riley, M. M. Andino, D. De Antonis, C. Beels,
J. DeGeorge, A. G.M. De Knaep, D. Ellison, J. A. Fagerland, R. Frank, B. Fritschel,
S. Galloway, E. Harpur, C. D.N. Humfrey, A. S. Jacks, N. Jagota, J. Mackinnon,
G. Mohan, D. K. Ness, M. R. O’Donovan, M. D. Smith, G. Vudathala, and L. Yotti.
A rationale for determining, testing, and controlling specific impurities in pharmaceu-
ticals that possess potential for genotoxicity. Regulatory Toxicology and Pharmacology,
44(3):198–211, 2006.
[36] J. Zhuang, X. Xing, D. Wang, Z. Du, J. Wang, Y. Dong, W. Yu, and S. H. Siyal.
Toxicity assessment of the extractables from multi-layer coextrusion poly ethylene bags
exposed to pH=5 solution containing 4% benzyl alcohol and 0.1 M sodium acetate.
Regulatory Toxicology and Pharmacology, 94:47–56, 2018.
[37] I.C. Munro, A.G. Renwick, and B. Danielewska-Nikiel. The Threshold of Toxicological
Concern (TTC) in risk assessment. Toxicology Letters, 180(2):151–156, 2008.
[38] D. Jenke and T. Carlson. A Compilation of Safety Impact Information for Extractables
Associated with Materials Used in Pharmaceutical Packaging, Delivery, Administra-
tion, and Manufacturing Systems. J. Pharm. Sci. Technol., 68(5):407–455, 2014.
[39] M. Nagao, W. P. Beierschmitt, D. J. Ball, A. J. Shaw, and S. Beck. The ELSIE
Extractables and Leachables Database. Pharma. Outsourcing, 2011.
[40] G. Patlewicz, N. Jeliazkova, R.J. Safford, A.P. Worth, and B. Aleksiev. An evaluation
of the implementation of the Cramer classification scheme in the Toxtree software.
SAR and QSAR in Environmental Research, 19(5-6):495–524, July 2008.
[41] X. Ding, X. Yu, and D. Wood. Extractables and Leachables Study Approach for
Disposable Materials Used in Bioprocessing. BioPharm. International, 21(2), 2008.
[42] R. D. Jenke, J. Story, and R. Lalani. Extractables/leachables from plastic tubing
used in product manufacturing. International Journal of Pharmaceutics, (315):75–92,
2006.
[43] E. Demir, S. Kocaog˘lu, and B. Kaya. Assessment of genotoxic effects of benzyl deriva-
tives by the comet assay. Food and Chemical Toxicology, 48(5):1239–1242, May 2010.
[44] A. L. Branen. Toxicology and biochemistry of butylated hydroxyanisole and butylated
hydroxytoluene. Journal of the American Oil Chemists’ Society, 52(2):59, February
1975.
BIBLIOGRAPHY 131
[45] G.M Williams, M.J Iatropoulos, and J Whysner. Safety Assessment of Butylated
Hydroxyanisole and Butylated Hydroxytoluene as Antioxidant Food Additives. Food
and Chemical Toxicology, 37(9-10):1027–1038, 1999.
[46] B. Athenstaedt. Development of GC-MS methods for the identification and quantifi-
cation of leachables from plastic packaging in dialysis solutions. PhD thesis, Duisburg,
2013.
[47] I. Markovic. Evaluation of safety and quality impact of extractable and leachable
substances in therapeutic biologic protein products: a risk-based perspective. Expert
Opin. Drug Saf., 6(5):487–491, 2007.
[48] Y. Gao and N. Allison. Extractables and leachables issues with the application of single
use technology in the biopharmaceutical industry: Extractables and Leachables in
Disposable Manufacture. Journal of Chemical Technology & Biotechnology, 91(2):289–
295, 2016.
[49] A. Colas, R. Malczewski, and K. Ulman. Silicone Tubing For Pharmaceutical Pro-
cessing. Pharma. Chem., pages 30–36, 2004.
[50] A. Hauk, E. Jurkiewicz, I. Pahl, T. Loewe, and R. Menzel. Filtration membranes -
Scavengers for leachables? European Journal of Pharmaceutical Sciences, April 2018.
132 BIBLIOGRAPHY
Chapter 5
Simulation-studies
5.1 Introduction
Alternative study designs for improved assessment of potential impurities in pharmaceu-
tical processing are an active area of research, marked as a hot topic in the most recent
extractable and leachable conferences [1]. Simulation based studies are an emerging and
promising alternative to real world testing. This new method of testing is an intermediate
step between classic extractable- and leachable-studies. Classical extractable studies are
well known for the comprehensive and almost exhaustive assessment of tentative leach-
ables (see chapter 3). Simulation-studies provide more restrictive profiles comprising only
substances which are most likely to leach out, thus providing a more realistic assessment.
Furthermore, simulation-studies can estimate the potential amount of leachables without
the need of real-sample analysis by leachable-studies (described in chapter 4). This new
concept offers a real alternative to the best practice protocol of the BioPhorum Opera-
tion Group (BPOG) [2, 3]. The best practice guidelines recommend to assess the risks
for biopharmaceutical manufacturing posed by SUSs using multiple analytical methodolo-
gies and a broad range of extraction solvents. The guidelines also highlight important
parameters to consider when designing a study to ensure optimal information from the
generated extractions. For example extracting solvents stronger than the drug product are
recommended to obtain qualitative extraction profiles to be used for establishing quality
control criteria. However, this design is time intensive with respect to preparation and
evaluation. Simulation-studies on the other hand are intended to use more realistic and
adaptable parameters, with respect to contact time and contact solution. Additionally, as
each SUS application and its contact to the individual drug product varies, customized
extraction design is achieved by simulation-studies. Finally, the surface to volume ratio is
adjusted in order to increase both the concentrations of probable leachables and the rates
of migration of these into the solvent [4, 5].
According to USP <665> [6] the difference between a drug product leachable-study and
a simulation-study with respect to the study design is that the drug product formulation is
replaced with a simulating solvent. Depending on the extraction purposes the drug product
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Figure 5.1: The relationship between extractables and leachables can vary from a full and
complete correlation to a poor and largely incomplete correlation depending on the study-
design, with extractables representing worst-case leachables. However, simulation-studies
typically correlate well with leachables without a unnecessary large overhead.
can be mimicked by a precise extractation medium with similar propensity to extract chem-
icals from the components. A possible outlay of a simulating solvent with this advantage
was shown by R. Haep et al. [7]. The authors used a screening assay with glutathione as a
surrogate compound, which can be used in the SUS selection process to identify polymers
with a risk of protein-reactive compounds leaching. This kind of testing detects leachables
that otherwise might not be identified during a classical leachable-study, as they can be
masked by reactions with the active protein of the drug product. These reaction products
were also present under more realistic conditions during the simulation study. Therefore,
simulation studies are not only an approach for more realistic extractable-studies, but also
provide adjusted leachable-study with a clear proof of migrating substances by simulating
the product and/or the process parameters.
In this chapter we demonstrate the potential of a new kind of simulation study as an al-
ternative design to the classical extractable & leachable approach. Instead of analyzing the
drug product with a classical leachable-study as described in chapter 4 or applying a simu-
lating solvent, all used SUS were tested for residual additives after application in the drug
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filling process. The post-application extractable footprint was compared to extractable
footprints of identical but unused SUSs. This enabled the identification and quantifica-
tion of substances that leached into the drug product during the application of the SUS.
This approach indirectly estimates the leachable contamination without analyzing the drug
product. Hence, this method is particularly well suited in cases where minimal disruption
of the manufacturing process is desirable. Furthermore, the controlled test matrix in sim-
ulation studies is easy to analyze, due to the lack of any interfering drug product. At the
same time the drug manufacturing process can remain largely unchanged as compared with
real world processing. The simulation study, described in this work, was conducted with a
filling tubing, which was reused over several drug product batches. The silicone tubing was
used for up to six drug product runs, as it can be cleaned and sterilized in place (CIP/SIP).
The repeated use of the silicon tubing enables the assessment of the leaching and the po-
tential uptake of additives by the silicone matrix over the number of applications. To this
end, some tubes were analyzed after 1, 3 or 6 runs in the manufacturing process. The
majority of leachables can be expected in the first run, as most (semi-)volatile additives
are likely to leach at first contact to the product. However, during each application the
tube is exposed to mechanical stress by squeezing, which can potentially lead to variable
leachable outcome in repeated use. Therefore, identified leachables were compared among
tubes with different number of applications. All detected substances were also compared
to the extractable-footprint obtained in chapter 3 (Table 3.2), to exclude substances that
were absorbed by the porous silicone material, as described in subsection 4.3.2. Addition-
ally, the outcome was compared to the results of the leachable-study (chapter 4) of the last
processing step, the filling.
5.2 Materials and Methods
5.2.1 Chemicals
Sample analysis was performed with thermal desorption gas chromatography mass spec-
trometry (TD-GC-MS) (TDS 3 TDSA 2 Gerstel GmbH, Muelheim an der Ruhr, 7890B
GC-System, 5977A MSD, Agilent Technologies, Waldbronn, Germany) and ultra perfor-
mance liquid chromatography (UPLC/QTOF-MS/MS) (Xevo G2-S Tof, Acquity, Wa-
ters GmbH, Eschborn, Germany) combined with electron spray ionization (ESI). Nine
spiking substances were added to allow for semi-quantitative analysis with GC-MS and
UPLC/QTOF-MS/MS. These substances were selected as they are commonly observed
leachables. GC analytic: Tetrahydrofurfuryl (THF) methacrylate logKO/W : 1.8; Di-
ethyl-phthalate logKO/W : 2.45; 3,5-Di-tert-butyl-4-hydroxybenz-aldehyde logKO/W : 4.2
and Butylated hydroxyltoluene (BHT) logKO/W : 5.3. UPLC analytic, positive ionization-
mode: 2-(2-hydroxy-5-methylphenyl) benzotriazole (UVA P) logKO/W : 6.1; 2-(2H-Benzo-
triazol-2-yl)-4,6-bis(1,1-di-methylpropyl) phenol (Tinuvin 328) logKO/W : 7.25; 2,5-Bis(5-
tert-butylbenzoxazol-2-yl) thiophene (Uvitex OB) logKO/W : 8.0; Tris(2,4-DI-tert-butyl-
phenyl) phosphite (Irgafos 168) logKO/W : 15.5; UPLC analytic, negative ionization-mode:
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1,3,5-Trimethyl-2,4,6-tris(3,5-di-tert-butyl-4-hydroxybenzyl) benzene (Irganox 1330)
log KO/W : 17.7; Pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-pro-
pionate) (Irganox 1010) logKO/W : 19.4. All substances were purchased from Sigma
Aldrich (Steinheim am Albuch, Germany) with purity > 97%. Water for Injection (WfI)
was prepared on a Milli-Q Advantage A10 system (Merck GmbH, Darmstadt, Germany).
Absolute ethanol (99.7% optigrade, Promochem LGC, Wiesel, Germany), methanol (UPLC-
grade, Biosolve, Dieuze, France) and ethyl acetate (99.8% Sigma Aldrich) were applied as
solvents and/or eluents. Formic acid (Sigma Aldrich) was used for LC ion suppression and
non-treated glass wool (Sigma Aldrich) for direct TD spiking application.
5.2.2 Sample Preparation, Extraction and Analytic Methods
The filling tubing (see Table 4.1 in chapter 4) was reused for up to six batches of drug
product 1 (see Table 4.2 in chapter 4). To assess the impact of repeated use, filling tubes
were analyzed after 1, 3 or 6 applications, respectively. The disposable tubing was gently
flushed with water (at room temperature) prior to examination, in order to wash residual
adherent protein off the inner wall of the tube. The tubes were filled with 6 mL of either
pure WfI or a WfI/ethanol mix, depending on the subsequent analysis, and sealed with
glass stoppers. Heated extraction was performed for three days in glass bottles containing
∼ 10 mL of extraction solvent, in order to prevent evaporation. Blank measurements were
performed with aliquots of the extracting solvents in glass bottles and carried out under
identical conditions. Stir-bar sorptive extraction (SBSE) was performed with the generated
WfI samples using a 10 mm glass-encapsulated, magnetic stir-bar coated with 24 µL of
pure polydimethylsiloxane (PDMS) (Twister, Gerstel GmbH). Subsequent analysis was
performed with direct thermal desorption (TD) with subsequent GC-MS. The WfI/ethanol
samples were directly analyzed with UPLC/QTOF-MS/MS analytic without any sample
preparation.
TD-GC-MS Measurement of (Semi-)Volatile Substances
Extraction with WfI was performed at 100◦C. For the GC analysis, 1 mL sample was
mixed with 4 mL WfI to ensure complete submersion of the stir-bar. The PDMS coated
stir-bar was then exposed to the solution for 1 h at a stirring speed of 800 rpm and a
temperature of 19◦C. Following the extraction step, the stir-bar was rinsed with WfI, dried
by dabbing and placed in the autosampler (operating parameters listed in chapter 2). Blank
measurements were performed by immersing the stir-bar in the blank solution, to verify the
system contamination by estimating the background noise. Reference measurements were
done with stir-bars subjected to THF-methacrylate and BHT-aldehyde spiked WfI. For this
purpose, the spiking standards were dispersed in ethanol by sonication at a concentration
of 0.1 g/L and diluted with WfI to simulate a contamination of 0.1 ppm.
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UPLC/QTOF-MS/MS Measurement of Non-Volatile Substances
For the extraction of residual, non-volatile substances in the filling tubing, the tubes were
filled with the solvent mix and extracted at 70◦C. Note that the temperature was chosen
just below the boiling point of ethanol. Non-volatile compounds in the generated extract-
solutions were identified by UPLC/QTOF-MS/MS analytic [8] with operating parameters
listed in chapter 4. Reference measurement was performed by injecting pre-defined spiking
substances on water ethanol basis into the UPLC-system, simulating a 0.1 ppm contam-
ination. The compounds were identified by matching accurate monoisotopic masses to a
proprietary, internal database (Roche GmbH) and the handbook of Bolgar et al. [9].
5.3 Results
5.3.1 Impurity-Output during Single Batch Applications
All residual substances found in the different filling tubes after varying number of reusage
are depicted in Figures 5.2a-5.2d. All semi-volatile substances detected with TD-GC-
MS analysis exhibited decreased concentration for increased number of aplications (Fig-
ure 5.2a), except benzaldehyde (Figure 5.2d), which displayed a largely stable concen-
tration fluctuating around 0.04 ppm over the six batches. Even glycerol 1,2-diacetate
and its breakdown fragments 1,2,3-propanetriol, 1-acetate and hexanedioic acid, mono(2-
ethylhexyl)ester, which were found in high concentrations after one usage, decreased dras-
tically in concentration. Also a decrease in concentration for higher molecular weight
substances was observed by UPLC/QTOF-MS/MS analysis (Figure 5.2b). The most sig-
nificant decrease was determined for oligomers, including silixones and ubiquitous polyether
polypropylene glycols. On the other hand, some substances with lower mobility exhibited
increased concentration after repeated application (Figure 5.2c). The largest increase in
concentration was observed for the monomer caprolactam increased (0.55 ppm over the five
repetitions). An unknown substance with a mass-to-charge ratio of 250.1280 m/z was the
only substance which exhibited an increase in concentration that could not be identified
as an impurity of the filling tubing (by comparison to the extractable-footprint, chapter 4
Table 3.2). Neither a decrease nor an increase was observed for the plasticizer triacetin
and its fragment glycerine acetate (Figure 5.2d).
5.3.2 Determination of the Impurity-Outcome
Based on the assumption of a constant leaching out of substances by the filling tubing
during its application within the drug product processing, the simulation-study provides
quantitative estimates of the amount of leachables in the final drug product. For example,
polypropylene glycol, the substance observed with the highest concentration, exhibits a
decrease of 0.442 ppm for two repeated applications (number of applications 1-3). Hence,
the following quantity of leachable can be assumed to have migrated into the drug product:
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Figure 5.2: Residual impurities in the silicone matrix of the filling tube, extracted by
static extraction, detected with TD-GC-MS and UPLC/QTOF-MS/MS analytic and semi-
quantitatively assessed over a varying number of repeated applications. Substances are
grouped based on the exhibited concentration behavior for a varying number of applica-
tions.
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mLeachable = cLeachable ∗ VExtract = 0.442ppm ∗ 6mL = 2.65µg (5.1)
Accordingly a single filling tube is expected to excrete 2.65 µg of polypropylene glycol
between the first and third repeated application. In the corresponding two batches a drug
volume of 122.5 L was filled and was exposed to the tube, resulting in a leachable contam-
ination of 1.1 * 10−5 mg per drug product volume L (= 11 ppt). This can be considered a
worst case estimation as potential leakage during the intermediary CIP/SIP procedures of
high temperature and pressure are not taken into account. Furthermore, higher leachable
contamination is expected compared with the actual drug product filling, as higher tem-
peratures are applied.
Furthermore, the impurity estimation based on the simulation study was compared
to the observed leachables during the drug-product filling in chapter 4. The following
three leachables were found in the last sample spot, the vial, but not in the filtration-
vessel before (also listed in table 4.15): 1-Hexadecanol with a concentration of 0.009 ppm,
ethanol, 2-(2-butoxyethoxy)-, acetate with a concentration of 0.025 ppm, both detected in
drug product 1, and acetophenone with a concentration of 0.011 ppm in drug product 3.
All three substances were also detected in the simulation-study, although partially in an
unoxidized form and in much lower concentrations.
5.4 Discussion
A simulation-study was applied as a minimally disruptive alternative to conventional ex-
tractable and leachable studies. As a hybrid method between extractable and leachable-
studies, simulation-studies potentially offer time efficient screening of impurities while also
providing quantitative estimation.
The present simulation study showed only limited agreement with the reference result
of the extractable and leachable studies, respectively. Only few of the substances detected
in the extractables study of chapter 4 were observed in the simulation study (5.1). The
leachable profile obtained in the simulation study showed also not exact agreement with
the production line leachable study in chapter 4, as shown in 5.2. Our simulation-study
indicates a total amount of leachables in the range of parts per trillion (ppt). These
calculations are based on the worst case assumption that no leaching had taken place
during the CIP/SIP procedure and steady leaching is observed. However, the simulation
studies could not explain larger concentrations up to 0.025 ppm, as observed in the real-
world leachable-study. This discrepancy warrants further investigation.
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Table 5.1: Extractable-footprint conducted for the unused filling tubing (see chapter 4).
Comparison to the Leachable-footprint (see chapter 4 - Leachables that occur between
position 4 and 5) and to the Simulation-footprint of the used filling tubes.
Chemical
group
Extractable-footprint Overlap
of the
Leachable-
footprint
Overlap
of the
Simulation-
footprint
Acids n-Decanoic acid9-Hexadecenoic acid
Alcohols
Ethanol, 1-(2-butoxyethoxy)-
Ethanol, 2-(2-ethoxyethoxy)-
Ethanol, 2-(2-butoxyethoxy)-, acetate, x
Benzyl alcohol
2-Hexyl-1-octanol
Cyclohexanol, 4-(1,1-dimethylethyl)-
2-Propanol, 1-(2-methoxy-1-methylethoxy)-
1-Dodecanol
1-Decanol,2-hexyl-,
1-Tetradecanol
2-Methyl-1-undecanol
1-Hexadecanol, 2-methyl- x
Aldehydes C9H18O − C12H24O (Nonanal – Dodecanal)
Alkanes Straight chain and non-straight alka-
nes: C12H26 − C28H58 (Dodecane / 9-
methylheptadecane - Octacosane)
Alkene 17-Pentatriacontene
Amides 2-Pyrrolidinone, 1-methyl-,4(1H)-Pteridinone, 2-amino-
Aromatic
compounds
Acetophenone x x
Benzaldehyde x
1,3-Di-tert-butylbenzene
Benzene, 1,2,4-trimethyl-5-(1-methylethyl)-
2,6-Di-tert-butyl-hydroquinone
unknown aromatic compound
2-Octyl benzoate
2,6-Di-tert-butyl-hydroquinone
Phenol, 2,4-di-t-butyl-6-nitro-,
Ester
Glycerol 1,2-diacetate
1-Methoxy-2-propyl acetate (Glycerol)
Nonanoic acid, 9-oxo-, methyl ester
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Dodecanedioic acid, bis(tert-
butyldimethylsilyl) ester
Pentanoic acid, 2,2,4-trimethyl-3-
carboxyisopropyl, isobutyl ester
m-Toluic acid, 4-hexadecyl ester
Pentadecanoic acid, 14-methyl-, methyl ester
Acetic acid, phenylmethyl ester
Methacrylic acid, nonadecyl ester
Hexadecanoic acid, 2-methylpropyl ester
Ketone Benzophenone
Lactams Caprolactam
Polycyclic
aromatic
9,9-Dimethyl-9-silafluorene
Lactams Caprolactam
Phosphates Triethyl phosphate xTributyl phosphate
Phthalate
Diethyl Phthalate
Diisobutyl phthalate
Butyl Isodecyl Phthalate
Benzoic acid, 4-(4-butylcyclohexyl)-, 2,3-
dicyano-4-ethoxyphenyl ester
Siloxanes Silanediol, dimethyl-; 2,5-
Bis[(trimethylsilyl)oxy]benzaldehyde; Cy-
closilioxanes (C6H18O3Si3 − C20H60O10Si10);
Siloxane chains (C7H21O2Si3 − C16H48O6Si7)
x
Triazine 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tri-
2-propenyl-
Table 5.2: Extractable-footprint conducted for the unused filling tubing (see chapter 4).
Comparison to the Leachable-footprint (see chapter 4 - Leachables that occur between
position 4 and 5) and to the Simulation-footprint of the used filling tubes.
m/z Extractable-footprint Overlap
of the
Leachable-
footprint
Overlap
of the
Simulation-
footprint
Pos.: 202,1807 C11H23NO2 99.99%
Pos.: 191,0239 C3H12O5P2 99.77%
Pos.: 173,0796 Triethylene glycol C6H14O4 96.05% x
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Pos.: 215,1260 Uvinul 3000 2,4-dihydroxybenzophenone
C13H10O3 tentative
Pos.: 217,1056
Neg.:
327,9723
C4H17N4O4P 94.86%
Pos.: 163,0611
Neg.:
327,9812
C5H14O2Si2 93.46% x
Pos.: 261,1310 Pentaethyleneglycol C10H22O6 98,85% x
Pos.: 199,0587 Glycerine acetate C7H12O5 99.99% x
Pos.: 305,1585 C8H25N4O6P 96.15%
Pos.: 114,0921 Caprolactam C6H11NO 99.99% x
Pos.: 177,1010 C8H14N2O 95.78%
Pos.: 349,1844
Pos.: 481,2631
Pos.: 525,2886
Polyethylene glycol, ubiquitous polyether
[C2H4O]nH2O 98.46%
x
Pos.: 255,0850 C7H19N2O3P 99.52% x
Pos.: 239,0900 Dimethyl 2-hydroxy-1,3-
cyclohexanedicarboxylate C10H16O5 84.72%
Pos.: 241,0700 Triacetin C9H13O6 99.99% x
Pos.: 273,1678 C7H23N8P 91.01%
Pos.: 205,0613 Triethyl phosphate C6H15O4P 99.99% x
Pos.: 244,1428 C8H18N7P 78.84% x
Pos.: 223,0946 Diethyl phthalate C12H14O4 99.99% x
Pos.: 249,1111 C9H21N2OP 88.30% x
Pos.: 227,1262 Unknown x
Pos.: 279,0070 Dibutyl phthalate C16H22O4 99,99% x
Pos.: 227,1266 C10H20O4 91.17%
Pos.: 371,2419 C17H41O2P3 71.94% x
Neg.:
170,9881
Unknown
Neg.:
471,2769
Unknown
Neg.:
1012,4156
Unknown
Neg.:
1142,0212
Unknown
As expected, a decrease in concentration of volatile substances was observed for re-
peated use of silicon tubings. However, half of the detected substances (those with higher
molecular weight) exhibited an increase in concentration. These results corroborate that
144 5. Simulation-studies
substances with low molecular weight are starting to leach right from the first application,
while higher molecular weight substances are extracted comparatively late after increased
mechanical stress.
The present results demonstrate poor agreement in the assessed leachable profiles with
the reference leachable study and thus no improved accuracy compared to the extractable
study. Potential leaching in the SIP/CIP step introduces some additional uncertainty in
the quantification. Accordingly, improved accuracy in the quantitative assessment can be
expected for SUSs where no intermediate preparation steps are required. Furthermore,
the present study-design was based on the assumption that all tubes had the exact same
amount of additives polymerized in their matrix.
5.5 Conclusion
Simulation-studies have been previously presented as an emerging technique for simple
and minimally disruptive detection of impurities in pharmaceutical filling lines. However,
no accurate leachable identification could be observed within this study compared to the
well-known extractable & leachable concept especially for critical manufacturing processes.
However, extensive testing is warranted to establish the level of accuracy of simulation
studies in various conditions and qualify this method for different SUSs.
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Chapter 6
Final Summary & Outlook
The aim of this thesis was to extent the current knowledge around the analytical charac-
terization and the migration behaviour of leachables in bio-pharmaceutical drug product
manufacturing lines, equipped with diverse single-use systems (SUSs) such as disposable
bio-process bags, sterile filters and silicone tubing. chapter 1 provides the background for
the various analytical methods and extraction studies used to analyze real-life leaching of
polymer-based impurities.
In chapter 2 the applicability of stir-bar sorptive extraction (SBSE) was evaluated for
the detection of trace amounts of leachables in pharmaceutical manufacturing. The im-
pact of various drug product formulations on the extraction and concentration efficiency
was assessed via spiking/simulation studies. Furthermore, the suitability of the absorption
method was studied by demonstrating the uptake of a wide range of potential leachables,
despite a large variety in the volatility and the log KO/W -setting of the substances. No
matrix inhibition by large protein drugs and only mild reduction of recovery were observed
in the relevant pH range. In contrast, the chemical category of the extracted substance
and the alcoholic content of the matrix-solution had a higher impact. Nonetheless, all
limits of detection were found to be well below the applicable thresholds in a worst case
scenario analysis. This was further corroborated by a high linearity of the measurement
technique. The optimal use of this technique, including the effect of the stir-bar coating
material, the combination of different stir-bars and the stirring time and speed, was ex-
amined for protein-based drug matrices. Additionally, a conditioning step of the stir-bar,
used to mitigate the inhibitory effects of the drug matrix, was investigated . Our results
indicate that in combination with gas-chromatography mass-spectrometer (GC-MS), the
conventional poly-di-methyl-siloxane (PDMS) coating achieves better recovery on average
compared with the ethylene-glycol-(EG)-PDMS. Furthermore, despite inhibitory effects of
alcoholic solutions the SBSE method combined with a PDMS coated stir-bar reached sat-
isfactory sensitivity, and large improvements compared with direct injection of the sample
into the GC-MS system. Preceding stir-bar preparation consisting of a simple soaking step
improved the enrichment, effectively lowering the limit of detection.
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chapter 3 elaborates on the concept of extractable studies to delineate the leachable
candidates for each SUS in prior to manufacturing. Our results validate that by modelling
extraction parameters the detection of potential leachables is possible. It can be distin-
guished between static and thermal extraction-procedures, where the polymer is tested
with different solvents and contact-times, or by direct exposure of the material to different
heat-stages. Depending on the intensity of the extraction conditions, the amount and type
of extracted substances can vary widely. For the detection of more volatile substances with
GC-MS analytic, direct material thermal desorption of polymers was shown to be a fast
and easily applicable study-design to obtain comprehensive additive-fingerprints of each
SUS. Finally to fully characterize the samples, elemental analysis of inorganic impurities
was conducted with inductively coupled plasma (ICP)-MS analytic, in addition to the GC-
MS analytic.
chapter 4 describes the major contribution of this work, direct assessment of leach-
ables in real-world filling lines. Multiple samples were drawn from various positions in
a conventional SUS equipped manufacturing line during commercial processing of repre-
sentative drug products. Exhaustive and quantitative leachable-profiles were generated
for each sampling point using previously introduced stir-bar sorptive extraction (SBSE)
with polydimethylsiloxane (PDMS) and ethylene glycol(EG)-PDMS coated stir-bars, with
subsequent TD-GC-MS and ultra performance liquid chromatography (UPLC)-MS. The
majority of contaminating substances exhibited a consistent decrease for all drug products
and independent of the investigated SUSs. This can be explained by dilution with buffer-
feed and by absorption of leachables in filters and silicon tubing. To corroborate the latter,
absorption was independently proven in a mock set-up. Additionally, all leachables in
the manufacturing line were found in extremely low concentrations, all below toxicological
thresholds. Furthermore, all substance were found to be non-genotoxic. The previously
obtained extractable-footprint also enabled to trace back each leachables to the SUSs,
where they originated. This data shows that most of the detected leachables, were ob-
served right from the start of the filling line and were likely already found in the delivered
API. This indicates that harsher processing parameters necessary in drug manufacturing
on substance side lead to increased leaching-rates. Benign conditions in the filling line, on
the other hand, pose no threat in terms of leachable contamination and most often lead
to a decrease in leachable concentration. Neither a common source of leaching could be
identified within the filling-line nor a specific product influence on quality or quantity of
leachables. Changes in the pH-value of the matrix were the product property that was
found to markedly affect the amount of leaching during manufacturing. Specifically, no
significant impact of the active ingredients on the leachable-outcome was observed.
chapter 5 explores a novel strategy for migration-studies, suited for real-life filling lines.
So called simulation studies are an intermediate step between classic extractable- and
leachable-studies. Simulation studies generate quantitative leachable estimates by simu-
lating the stress during the manufacturing process in a controlled environment. Simula-
tion studies provide more restrictive leachable estimates compared with the comprehensive
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worst-case profiles obtained in extractable-studies. Furthermore, simulation studies pro-
vide approximate quantification of the expected impurities. However, the leachable-profiles
obtained in simulation studies do not necessarily form a superset of the final real-life leach-
able outcome. In our experiments simulation studies were used to evaluate the leaching-
behaviour of a reusable filling-tubing, which was applied over six batch-fillings. The results
shows a decrease in concentration of volatile substances with increasing number of repeated
applications of the reusable system. Furthermore, substances with low molecular weight
leached out in the first applications of the reuseable system. Conversely, substances with
higher molecular weight were extracted with increased concentration after the polymer
matrix was affected by mechanic stress.
SUS are rapidly gaining importance in pharmaceutical manufacturing and become in-
creasingly established as industry standard. To date extractable studies are the method
of choice to ensure patient safety in light of leachable contamination of the drug product.
Our results demonstrate that extractable studies are suitable for delineating a superset of
potential leachables. However, novel results based on the comparison to real-world leach-
able measurements also show that extractable-footprints lead to overly conservative use
of SUS and can lead to restriction of efficient drug manufacturing based on inaccurate
worst-case estimations. In this work we explored the use of leachable detection during the
commercial filling process, a process which sheds new light on the actual patient expo-
sure. Initial extractable footprints can be used to design tailored measurement techniques
sensitive to the expected contaminants. Tailored measurements enable in-line leachable as-
sessment with high accuracy and sensitivity and open up new possibilities for commercial
leachable studies, without the repercussions of overly conservative worst-case estimations
based on extractable studies. Our results also demonstrate that multiple SUSs act as
leachable scavenger in the manufacturing process. To minimize leachable contamination
in manufacturing further this concept warrants exploration as dedicated “leachable filter”
for pharmaceutical manufacturing. Besides filter SUSs, PDMS and EG-PDMS coating
showed excellent absorption, facilitating sensitive measurements with the SBSE technique.
This material property could conceivably be exploited for improved scavenging technology
within the filling line, essentially eliminating any residual risks associated with polymer
leaching. While accurate evaluation and monitoring are paramount to ensure safe use of
SUS the results presented in this thesis corroborate the usefulness of this novel material
in pharmaceutical manufacturing. Hence, techniques, such as proposed in this thesis, es-
pecially when established for improved in-line use of SUS system, will eventually facilitate
large scale use of novel, efficient and safe manufacturing techniques and ensure effective
and widespread access to crucial drugs for those who are in need.
